

## **Quarterly information (ITR)**

### **Diagnósticos da América S.A.**

June 30, 2015

With Independent Auditor's Review Report

## Contents

### Company Data

Capital Composition .....	1
Cash Earnings .....	2

### Individual Quarterly Financial Information

Statement of Financial Position - Assets .....	3
Statement of Financial Position - Liabilities .....	4
Statement of Income .....	5
Statement of Comprehensive Income .....	6
Statement of Cash Flows .....	7

### Statement of Changes in Equity

1/1/2015 to 6/30/2015 .....	8
1/1/2014 to 6/30/2014 .....	9
Statement of Value Added .....	10

### Consolidated Quarterly Financial Information

Statement of Financial Position - Assets .....	11
Statement of Financial Position - Liabilities .....	12
Statement of Income .....	13
Statement of Comprehensive Income .....	14
Statement of Cash Flows .....	15

### Statement of Changes in Equity

1/1/2015 to 6/30/2015 .....	16
1/1/2014 to 6/30/2014 .....	17
Statement of Value Added .....	18
Comments on the Company's Performance .....	19
Notes to Quarterly Financial Information .....	24
Other Information Considered Relevant by the Company .....	72

### Reports and Representations

Independent Auditor's Review Report on Quarterly Financial Information .....	73
Opinions and Statements/Statement of Officers on the Quarterly Financial Information .....	75
Opinions and Declarations/Statement of Officers on the Independent Auditors Review Report .....	76

**Company data/Capital Composition**

<b>Number of shares (Units)</b>	<b>Current quarter 06/30/2015</b>
Paid-in capital	
Common shares	311,803,015
Preferred shares	-
Total	311,803,015
Treasury shares	
Common shares	1,052,459
Preferred shares	-
Total	1,052,459

**Company Data/Cash Earnings**

<b>Event</b>	<b>Approval</b>	<b>Earnings</b>	<b>Initial Payment</b>	<b>Share</b>	<b>Class of Share</b>	<b>Earnings per share (Reais / Share)</b>
Annual General Meeting	4/23/2015	Dividends	6/03/2015	Common		0.06289

## Individual Quarterly Financial Information/Statement of Financial Position - Assets

(R\$ in thousands)

Code	Description	Current quarter 06/30/2015	Previous year 12/31/2014
1	Total assets	4,678,750	4,480,272
1.01	Current assets	1,208,541	1,165,193
1.01.01	Cash and cash equivalents	301,099	240,267
1.01.02	Marketable securities	58,585	51,674
1.01.02.01	Marketable securities at fair value	58,585	51,674
1.01.02.01.01	Marketable securities	58,585	51,674
1.01.03	Accounts receivable	608,507	569,943
1.01.03.01	Trade accounts receivable	608,507	569,943
1.01.04	Inventories	59,628	65,025
1.01.06	Taxes recoverable	134,593	139,211
1.01.06.01	Current taxes recoverable	134,593	139,211
1.01.07	Prepaid expenses	7,327	1,015
1.01.08	Other current assets	38,802	98,058
1.01.08.02	Assets held for sale	-	63,985
1.01.08.03	Other	38,802	34,073
1.01.08.03.03	Accounts receivable for the sale of subsidiaries	16,987	-
1.01.08.03.20	Other receivable	21,815	34,073
1.02	Non-current assets	3,470,209	3,315,079
1.02.01	Long-term receivables	229,615	149,123
1.02.01.01	Marketable securities at fair value	111,344	15,427
1.02.01.01.01	Marketable securities	111,344	15,427
1.02.01.03	Accounts receivable	400	558
1.02.01.03.01	Trade accounts receivable	400	558
1.02.01.07	Prepaid expenses	682	762
1.02.01.08	Receivables from related parties	4,658	70,951
1.02.01.08.02	Receivables from subsidiaries	4,658	70,951
1.02.01.09	Other non-current assets	112,531	61,425
1.02.01.09.04	Judicial deposits	64,534	61,267
1.02.01.09.05	Other non-current assets	220	158
1.02.01.09.06	Accounts receivable for the sale of subsidiaries	47,777	-
1.02.02	Investments	263,162	204,986
1.02.02.01	Equity interest	262,763	204,307
1.02.02.01.02	Investments in subsidiaries	262,763	204,307
1.02.02.02	Investment properties	399	679
1.02.02.02.20	Others	399	679
1.02.03	Property and equipment	678,959	652,780
1.02.04	Intangible assets	2,298,473	2,308,190
1.02.04.01	Intangible assets	2,298,473	2,308,190

## Individual Quarterly Financial Information/Statement of Financial Position - Liabilities

(R\$ in thousands)

Code	Description	Current quarter 06/30/2015	Previous year 12/31/2014
2	Total liabilities	4,678,750	4,480,272
2.01	Current liabilities	715,185	700,470
2.01.01	Social security and labor liabilities	141,127	119,676
2.01.02	Trade accounts payable	82,863	108,714
2.01.03	Tax liabilities	14,230	13,001
2.01.04	Loans and financing	386,074	353,566
2.01.04.01	Loans and financing	56,085	34,634
2.01.04.02	Debentures	329,989	318,714
2.01.05	Other liabilities	90,891	105,513
2.01.05.02	Other	90,891	105,513
2.01.05.02.01	Dividends and interest on equity payable	10	19,552
2.01.05.02.04	Taxes in installments	484	582
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,071	3,783
2.01.05.02.06	Uncovered liability of subsidiaries	174	4,459
2.01.05.02.08	Other payables	89,152	77,137
2.02	Non-current liabilities	1,182,618	1,008,530
2.02.01	Loans and financing	954,991	794,614
2.02.01.01	Loans and financing	45,579	51,289
2.02.01.02	Debentures	909,412	743,325
2.02.02	Other liabilities	14,301	23,070
2.02.02.02	Other	14,301	23,070
2.02.02.02.03	Taxes in installments	578	785
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	12,403	20,137
2.02.02.02.06	Other payables	1,320	2,148
2.02.03	Deferred taxes	144,234	131,792
2.02.03.01	Deferred income and social contribution taxes	144,234	131,792
2.02.04	Provisions	69,092	59,054
2.02.04.01	Provisions for tax, civil and labor risks	69,092	59,054
2.03	Equity	2,780,947	2,771,272
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	49,886	50,230
2.03.02.02	Special reserve for goodwill on merger	65,366	65,366
2.03.02.04	Granted options	1,425	1,769
2.03.02.05	Treasury shares	(16,905)	(16,905)
2.03.04	Revenue reserves	486,906	486,592
2.03.04.01	Legal reserve	36,693	36,693
2.03.04.05	Retained profit reserve	450,213	449,899
2.03.05	Retained earnings (accumulated losses)	10,018	0
2.03.06	Other comprehensive income	2	315

**Individual Quarterly Financial Information/Statement of Income****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 4/1/2015 to 6/30/2015</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Previous quarter 4/1/2014 to 6/30/2014</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
3.01	Revenue from products sold and/or services rendered	672,569	1,291,701	488,068	961,631
3.02	Cost of products sold and/or services rendered	(474,812)	(917,116)	(345,491)	(675,905)
3.03	Gross Profit	197,757	374,585	142,577	285,726
3.04	Operating income/expenses	(146,416)	(294,503)	(78,873)	(166,824)
3.04.02	General and administrative expenses	(150,970)	(293,231)	(109,166)	(224,167)
3.04.04	Other operating income	3,190	5,074	20	406
3.04.05	Other operating expenses	(1,684)	(6,661)	-	-
3.04.06	Equity pickup	3,048	315	30,273	56,937
3.04.06.01	Equity pick-up - Continuing operations	3,048	(1,315)	-	56,937
3.04.06.02	Equity pick-up - Discontinued operations	-	1,630	-	-
3.05	Income before financial income/expenses and taxes	51,341	80,082	63,704	118,902
3.06	Financial income/expenses	(30,905)	(57,623)	(26,789)	(51,805)
3.06.01	Financial income	27,646	43,921	13,653	29,028
3.06.02	Financial expenses	(58,551)	(101,544)	(40,442)	(80,833)
3.07	Income before income and social contribution taxes	20,436	22,459	36,915	67,097
3.08	Income and social contribution taxes	(10,714)	(12,441)	(5,180)	(6,767)
3.08.02	Deferred	(10,714)	(12,441)	(5,180)	(6,767)
3.09	Net income from continuing operations	9,722	10,018	31,735	60,330
3.11	Net income for the period	9,722	10,018	31,735	60,330
3.99	Earnings per share (reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0.03129	0.03224	0.10212	0.19414
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0.03127	0.03222	0.10205	0.19401

### Individual Quarterly Financial Information/Statement of Comprehensive Income

(R\$ in thousands)

<b>Code</b>	<b>Description</b>	<b>Current quarter 4/1/2015 to 6/30/2015</b>	<b>Accumulated current year 1/1/2015 to 6/30/2015</b>	<b>Previous quarter 4/1/2014 to 6/30/2014</b>	<b>Accumulated previous year 1/1/2014 to 6/30/2014</b>
4.01	Net income for the period	9,722	10,018	31,735	60,330
4.03	Comprehensive income for the period	9,722	10,018	31,735	60,330



**Individual Quarterly Financial Information/Statement of Cash Flows****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
6.01	Net cash from operating activities	182,952	173,129
6.01.01	Cash from operations	224,860	165,415
6.01.01.01	Net income for the period	10,018	60,330
6.01.01.02	Depreciation and amortization	85,517	71,692
6.01.01.03	Update of contingencies	20,717	13,652
6.01.01.04	Deferred taxes	12,441	6,767
6.01.01.05	Update of interest and exchange variation on loans	81,663	70,535
6.01.01.06	Gain on sale of property and equipment	4,043	483
6.01.01.07	Stock-option plan	(344)	737
6.01.01.08	Equity pickup	(315)	(56,937)
6.01.01.09	Update of accounts receivable for the sale of ownership interest	(5,276)	-
6.01.01.10	Provision for disallowance and default	17,443	(2,040)
6.01.01.11	Gain on interest in subsidiaries	203	196
6.01.01.12	Loss from sale of ownership interest	2,514	-
6.01.01.13	Update of accounts receivable for the sale of subsidiaries	(3,764)	-
6.01.02	Changes in assets and liabilities	(41,908)	7,714
6.01.02.01	Increase in trade accounts receivable and other receivables	(55,849)	(18,637)
6.01.02.02	(Increase) decrease in inventories	5,397	(2,638)
6.01.02.03	Increase in other current assets	13,195	1,406
6.01.02.04	Decrease in other non-current assets	8,763	5,383
6.01.02.05	Decrease (increase) in trade accounts payable	(25,851)	9,887
6.01.02.06	Decrease in accounts payable and provisions	12,437	12,313
6.02	Net cash used in investing activities	(213,801)	(83,753)
6.02.02	Additions to property and equipment	(86,551)	(45,258)
6.02.03	Additions to intangible assets	(19,471)	(8,030)
6.02.06	Dividends and interest on capital received	218	12,513
6.02.08	Investments in subsidiaries	(8,900)	(43,010)
6.02.09	Proceeds from sale of property and equipment	-	32
6.02.11	Marketable of securities	(120,600)	-
6.02.15	Rescue marketable securities	16,503	-
6.02.16	Proceeds from sale of subsidiaries	5,000	-
6.03	Net cash from (used in) financing activities	91,681	(337,641)
6.03.01	Loans received and debentures	438,596	3,405
6.03.02	Payment of loans and debentures	(256,774)	(236,926)
6.03.03	Dividends and interest on equity paid	(19,542)	(31,371)
6.03.04	Interest paid	(70,599)	(72,749)
6.05	Increase (Decrease) in cash and cash equivalents	60,832	(248,265)
6.05.01	At beginning of period	240,267	486,571
6.05.02	At end of period	301,099	238,306

**Individual Quarterly Financial Information/Statement of Changes in Equity - 1/1/2015 to 6/30/2015****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Paid-in capital</b>	<b>Capital reserve, granted options and treasury shares</b>	<b>Income reserve</b>	<b>Retained earnings</b>	<b>Other comprehensive income</b>	<b>Equity</b>
5.01	Opening balances	2,234,135	50,230	486,593	-	315	2,771,273
5.03	Adjusted opening balances	2,234,135	50,230	486,593	-	315	2,771,273
5.04	Transactions with shareholders	-	(344)	-	-	-	(344)
5.04.03	Granted options	-	(344)	-	-	-	(344)
5.05	Total comprehensive income	-	-	-	10,018	-	10,018
5.05.01	Net income of the period	-	-	-	10,018	-	10,018
5.06	Internal changes in equity	-	-	313	-	(313)	0
5.06.06	Depreciation of deemed cost	-	-	313	-	(313)	0
5.07	Closing balances	2,234,135	49,886	486,906	10,018	2	2,780,947

**Individual Quarterly Financial Information/Statement of Changes in Equity - 1/1/2014 to 6/30/2014****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Paid-in capital</b>	<b>Capital reserve, granted options and treasury shares</b>	<b>Income reserve</b>	<b>Retained earnings</b>	<b>Other comprehensive income</b>	<b>Equity</b>
5.01	Opening balances	2,234,135	49,727	423,409	-	943	2,708,214
5.03	Adjusted opening balances	2,234,135	49,727	423,409	-	943	2,708,214
5.04	Transactions with shareholders	-	737	-	-	-	737
5.04.03	Granted options	-	737	-	-	-	737
5.05	Total comprehensive income	-	-	-	60,330	-	60,330
5.05.01	Net income of the period	-	-	-	60,330	-	60,330
5.06	Internal changes in equity	-	-	123	-	(314)	(191)
5.06.04	Depreciation of deemed cost	-	-	314	-	(314)	-
5.06.05	Additional dividends paid	-	-	(191)	-	-	(191)
5.07	Closing balances	2,234,135	50,464	423,532	60,330	629	2,769,090

**Individual Quarterly Financial Information/Statement of Value Added****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
7.01	Revenue	1,455,977	1,055,251
7.01.01	Sales of goods, products and services	1,453,594	1,054,912
7.01.02	Other revenue	2,383	406
7.01.04	Reversal of allowance for doubtful accounts	-	(67)
7.02	Inputs acquired from third parties	(739,060)	(513,502)
7.02.01	Cost of products, goods and services sold	(513,245)	(366,348)
7.02.02	Materials, energy, third-party services and other	(225,815)	(147,154)
7.03	Gross value added	716,917	541,749
7.04	Retentions	(85,517)	(71,692)
7.04.01	Depreciation, amortization and depletion	(85,517)	(71,692)
7.05	Net value added produced	631,400	470,057
7.06	Transferred value added received	44,236	85,965
7.06.01	Equity pickup	315	56,937
7.06.02	Financial income	43,921	29,028
7.07	Total value added to be distributed	675,636	556,022
7.08	Distribution of value added	675,636	556,022
7.08.01	Personnel	329,941	243,895
7.08.02	Taxes, fees and contributions	169,417	114,267
7.08.03	Debt remuneration	166,260	137,530
7.08.04	Equity remuneration	10,018	60,330
7.08.04.03	Retained profits	10,018	60,330

## Consolidated Quarterly Financial Information/Statement of Financial Position - Assets

(R\$ in thousands)

Code	Description	Current quarter 6/30/2015	Previous year 12/31/2014
1	Total assets	4,817,663	4,609,536
1.01	Current assets	1,473,421	1,430,187
1.01.01	Cash and cash equivalents	362,807	274,986
1.01.02	Marketable securities	157,704	165,239
1.01.02.01	Marketable securities at fair value	157,704	165,239
1.01.02.01.01	Securities for trading	157,704	165,239
1.01.03	Accounts receivable	667,554	626,721
1.01.03.01	Trade accounts receivable	667,554	626,721
1.01.04	Inventories	66,215	71,942
1.01.06	Taxes recoverable	175,056	178,677
1.01.06.01	Current taxes recoverable	175,056	178,677
1.01.07	Prepaid expenses	7,432	1,015
1.01.08	Other current assets	36,653	111,607
1.01.08.02	Assets held for sale	-	77,347
1.01.08.03	Other	36,653	34,260
1.01.08.03.03	Accounts receivable for sale of subsidiaries	16,987	-
1.01.08.03.20	Other receivables	19,666	34,260
1.02	Non-current assets	3,344,242	3,179,349
1.02.01	Long-term receivables	294,917	145,222
1.02.01.01	Marketable securities at fair value	121,983	25,555
1.02.01.01.01	Marketable securities	121,983	25,555
1.02.01.03	Accounts receivable	2,210	2,785
1.02.01.03.01	Trade accounts receivable	2,210	2,785
1.02.01.06	Deferred taxes	55,777	53,028
1.02.01.06.01	Deferred income and social contribution taxes	55,777	53,028
1.02.01.07	Prepaid expenses	682	762
1.02.01.09	Other non-current assets	114,265	63,092
1.02.01.09.04	Judicial deposits	66,268	62,934
1.02.01.09.05	Other non-current assets	220	158
1.02.01.09.06	Accounts receivable for sale of subsidiaries	47,777	-
1.02.02	Investments	529	803
1.02.02.02	Investment Properties	529	803
1.02.02.02.01	Other	529	803
1.02.03	Property and equipment	709,057	683,228
1.02.04	Intangible assets	2,339,739	2,350,096
1.02.04.01	Intangible assets	2,339,739	2,350,096

## Consolidated Quarterly Financial Information/Statement of Financial Position - Liabilities and Equity

(R\$ in thousands)

Code	Description	Current quarter 6/30/2015	Previous year 12/31/2014
2	Total liabilities	4,817,663	4,609,536
2.01	Current liabilities	835,283	812,059
2.01.01	Social security and labor liabilities	153,204	131,774
2.01.02	Trade accounts payable	90,204	116,275
2.01.03	Tax liabilities	18,281	16,338
2.01.04	Loans and financing	480,227	433,643
2.01.04.01	Loans and financing	150,238	114,711
2.01.04.02	Debentures	329,989	318,932
2.01.05	Other liabilities	93,367	100,667
2.01.05.02	Other	93,367	100,667
2.01.05.02.01	Dividends and Interest equity on payable	100	19,622
2.01.05.02.04	Taxes in installments	698	956
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,071	3,783
2.01.05.02.20	Other accounts payable	91,498	76,306
2.01.07	Liabilities held for sale	-	13,362
2.01.07.02	Liabilities held for sale	-	13,362
2.02	Non-current liabilities	1,200,655	1,025,311
2.02.01	Loans and financing	954,991	794,614
2.02.01.01	Loans and financing	45,579	51,289
2.02.01.02	Debentures	909,412	743,325
2.02.02	Other liabilities	27,695	35,972
2.02.02.02	Other	27,695	35,972
2.02.02.02.03	Taxes in installments	3,333	3,559
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	23,042	30,265
2.02.02.02.20	Other accounts payable	1,320	2,148
2.02.03	Deferred taxes	148,055	134,849
2.02.03.01	Deferred income and social contribution taxes	148,055	134,849
2.02.04	Provisions	69,914	59,876
2.02.04.01	Provisions for tax, civil and labor risks	69,914	59,876
2.03	Consolidated equity	2,781,725	2,772,166
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	49,886	50,230
2.03.02.02	Special reserve for goodwill on merger	65,366	65,366
2.03.02.04	Granted options	1,425	1,769
2.03.02.05	Treasury Shares	(16,905)	(16,905)
2.03.04	Income reserves	486,906	486,592
2.03.04.01	Legal reserve	36,693	36,693
2.03.04.05	Retained profit reserve	450,213	449,899
2.03.05	Retained earnings (accumulated losses)	10,018	-
2.03.06	Other comprehensive income	2	315
2.03.09	Non-controlling interest	778	894

**Consolidated Quarterly Financial Information/Statement of Income****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 4/1/2015 to 6/30/2015</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Previous quarter 4/1/2014 to 6/30/2014</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
3.01	Revenue from products sold and/or services rendered	726,790	1,382,529	687,401	1,349,546
3.02	Cost of products sold and/or services rendered	(518,449)	(992,597)	(471,716)	(923,974)
3.03	Gross profit	208,341	389,932	215,685	425,572
3.04	Operating income/expenses	(160,141)	(319,757)	(140,281)	(283,893)
3.04.02	General and administrative expenses	(163,679)	(318,516)	(140,591)	(284,973)
3.04.04	Other operating income	3,647	5,710	310	1,080
3.04.05	Other operating expenses	(1,739)	(8,581)	-	-
3.04.06	Equity pickup	1,630	1,630	-	-
3.04.06.02	Equity pick-up - Discontinuing operations	1,630	1,630	-	-
3.05	Profit before financial income/expenses and taxes	48,200	70,175	75,404	141,679
3.06	Financial income/expenses	(25,764)	(48,509)	(28,412)	(53,054)
3.06.01	Financial income	33,929	54,108	19,664	39,255
3.06.02	Financial expenses	(59,693)	(102,617)	(48,076)	(92,309)
3.07	Income before income and social contribution taxes	22,436	21,666	46,992	88,625
3.08	Income and social contribution taxes	(10,963)	(11,478)	(15,141)	(28,092)
3.08.01	Current	(597)	(1,022)	(8,664)	(21,348)
3.08.02	Deferred	(10,366)	(10,456)	(6,477)	(6,744)
3.09	Net income from continuing operations	11,473	10,188	31,851	60,533
3.10	Net income from discontinuing operations	(1,630)	-	-	-
3.10.02	Net losses on assets discontinued operations	(1,630)	-	-	-
3.11	Consolidated net income for the period	9,843	10,188	31,851	60,533
3.11.01	Attributed to controlling shareholders	9,722	10,018	31,735	60,330
3.11.02	Attributed to non-controlling shareholders	121	170	116	203
3.99	Earnings per share (reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0,03167	0,03279	0,10250	0,19480
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0,03166	0,03277	0,10243	0,19466

**Consolidated Quarterly Financial Information/Statement of Comprehensive Income****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 4/1/2015 to 6/30/2015</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Previous quarter 4/1/2014 to 6/30/2014</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
4.01	Consolidated net income for the period	9,843	10,188	31,851	60,533
4.03	Consolidated other comprehensive income for the period	9,843	10,188	31,851	60,533
4.03.01	Attributed to controlling shareholders	9,722	10,018	31,735	60,330
4.03.02	Attributed to non-controlling shareholders	121	170	116	203



**Consolidated Quarterly Financial Information/Statement of Cash Flows****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
6.01	Net cash from operating activities	171,450	240,077
6.01.01	Cash from operations	229,812	237,624
6.01.01.01	Net income for the period	10,188	60,533
6.01.01.02	Depreciation and amortization	89,278	85,933
6.01.01.03	Update of contingencies	20,717	13,654
6.01.01.04	Deferred taxes	10,457	6,744
6.01.01.05	Update of interest and exchange variation on loans	95,288	68,862
6.01.01.06	Gain on sale of property and equipment	5,988	71
6.01.01.08	Stock-option plan	(344)	737
6.01.01.10	Provision for disallowance and default	24,410	684
6.01.01.12	Update of interest and exchange variation on marketable securities	(24,920)	406
6.01.01.13	Loss from sale of subsidiaries	2,514	-
6.01.01.14	Update of accounts receivable for the sale of subsidiaries	(3,764)	-
6.01.02	Changes in assets and liabilities	(58,082)	11,590
6.01.02.01	Increase in accounts receivable and other receivables	(63,946)	(72,970)
6.01.02.02	(Increase) Decrease in inventories	5,729	(8,570)
6.01.02.03	(Increase) Decrease in other current assets	6,086	(8,500)
6.01.02.04	Decrease in other non-current assets	2,600	57,873
6.01.02.05	Decrease (Increase) in trade accounts payable	(26,050)	15,701
6.01.02.06	Increase in accounts payable and provisions	17,499	28,146
6.01.03	Other	(280)	(9,137)
6.01.03.02	Income and social contribution taxes paid	(280)	(9,137)
6.02	Net cash used in investing activities	(175,270)	(47,944)
6.02.01	Additions to property and equipment	(90,791)	(56,524)
6.02.02	Additions to intangible assets	(19,471)	(8,380)
6.02.09	Proceeds from sale of property and equipment	-	208
6.02.11	Marketable securities	(137,507)	-
6.02.12	Rescue of marketable securities for trading	67,499	16,752
6.02.16	Proceeds from sale of subsidiaries	5,000	-
6.03	Net cash from (used in) financing activities	91,641	(286,193)
6.03.01	Loans received	438,596	63,405
6.03.02	Payment of loans	(256,805)	(243,360)
6.03.05	Payment of interest on loans	(19,541)	(31,372)
6.03.06	Dividends and interest on equity paid	(70,609)	(74,866)
6.05	Increase (Decrease) in cash and cash equivalents	87,821	(94,060)
6.05.01	At beginning of period	274,986	535,881
6.05.02	At end of period	362,807	441,821

**Consolidated Quarterly Financial Information/Statement of Changes in Equity - 1/1/2015 to 6/30/2015****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Paid-in capital</b>	<b>Capital reserve - granted options and treasury shares</b>	<b>Income reserve</b>	<b>Retained earnings</b>	<b>Other comprehensive income</b>	<b>Equity attributable to controlling shareholders</b>	<b>Non-controlling interest</b>	<b>Consolidated equity</b>
5.01	Opening balances	2,234,135	50,230	486,593	-	315	2,771,273	894	2,772,167
5.03	Adjusted opening balances	2,234,135	50,230	486,593	-	315	2,771,273	894	2,772,167
5.04	Transaction with shareholders	-	(344)	-	-	-	(344)	-	(344)
5.04.03	Granted options	-	(344)	-	-	-	(344)	-	(344)
5.05	Total comprehensive income	-	-	-	10,018	-	10,018	(116)	9,902
5.05.01	Net income for the period	-	-	-	10,018	-	10,018	(170)	9,848
5.05.02	Statement of Comprehensive Income	-	-	-	-	-	-	54	54
5.05.02.06	Non-controlling interest	-	-	-	-	-	-	54	54
5.06	Internal changes in equity	-	-	313	-	(313)	-	-	-
5.06.06	Depreciation of deemed cost	-	-	313	-	(313)	-	-	-
5.07	Closing balances	2,234,135	49,886	486,906	10,018	2	2,780,947	778	2,781,725

**Consolidated Quarterly Financial Information/Statement of Changes in Equity - 1/1/2014 to 6/30/2014****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Paid-in capital</b>	<b>Capital reserve - granted options and treasury shares</b>	<b>Income reserve</b>	<b>Retained earnings</b>	<b>Other comprehensive income</b>	<b>Equity attributable to controlling shareholders</b>	<b>Non-controlling interest</b>	<b>Consolidated equity</b>
5.01	Opening balances	2,234,135	49,727	423,409	-	943	2,708,214	596	2,708,810
5.03	Adjusted opening balances	2,234,135	49,727	423,409	-	943	2,708,214	596	2,708,810
5.04	Transaction with shareholders	-	737	-	-	-	737	-	737
5.04.03	Granted options	-	737	-	-	-	737	-	737
5.05	Total comprehensive income	-	-	-	60,330	-	60,330	199	60,529
5.05.01	Net income for the period	-	-	-	60,330	-	60,330	203	60,533
5.05.02	Others comprehensive income	-	-	-	-	-	-	(4)	(4)
5.05.02.06	Non-controlling interest	-	-	-	-	-	-	(4)	(4)
5.06	Internal changes in equity	-	-	123	-	(314)	(191)	-	(191)
5.06.04	Depreciation of deemed cost	-	-	314	-	(314)	-	-	-
5.06.05	Additional dividends paid	-	-	(191)	-	-	(191)	-	(191)
5.07	Closing balances	2,234,135	50,464	423,532	60,330	629	2,769,090	795	2,769,885

**Consolidated Quarterly Financial Information/Statement of Value Added****(R\$ in thousands)**

<b>Code</b>	<b>Description</b>	<b>Accumulated current period 1/1/2015 to 6/30/2015</b>	<b>Accumulated previous period 1/1/2014 to 6/30/2014</b>
7.01	Revenue	1,566,607	1,477,874
7.01.01	Sale of goods, products and services	1,565,508	1,476,878
7.01.02	Other revenue	1,099	1,080
7.01.04	(Reversal of) allowance for doubtful accounts	-	(84)
7.02	Inputs acquired from third parties	(802,738)	(700,101)
7.02.01	Cost of products, goods and services sold	(547,659)	(506,983)
7.02.02	Materials, energy, third-party services and others	(255,079)	(193,118)
7.03	Gross value added	763,869	777,773
7.04	Retentions	(88,418)	(85,894)
7.04.01	Depreciation, amortization and depletion	(88,418)	(85,894)
7.05	Net value added produced	675,451	691,879
7.06	Transferred value added received	55,741	39,255
7.06.01	Equity pickup	1,630	-
7.06.02	Financial income	55,111	39,255
7.07	Total value added to be distributed	731,192	731,134
7.08	Distribution of value added	731,192	731,134
7.08.01	Personnel	364,917	333,145
7.08.02	Taxes, fees and contributions	185,254	177,648
7.08.03	Debt remuneration	170,833	159,808
7.08.04	Equity remuneration	10,188	60,533
7.08.04.03	Retained profits	10,018	60,330
7.08.04.04	Non-controlling interest	170	203

## Notes to quarterly information

### Comments on the Company's Performance

#### Dear Shareholders,

Despite the slowdown of the Brazilian economy, with a decrease in job creation, we attained growth in our main business lines, which evidences that the initiatives we have taken in recent years are paying off and we continue to invest to ensure growth in coming years.

The focus remains on organic growth, as well as on the strengthening of all the business lines in which DASA operates, on improving our quality of care, strengthening our knowledge and technical quality, strengthening the alignment of our people with DASA's Culture and on decreasing employee turnover. We continue to work on improving our internal processes and we believe that the Company is making headway in its goal of being recognized worldwide for quality and efficiency in diagnostic medicine, providing its services to all social classes and remunerating its shareholders.

We kept our focus on improving the quality of our services. This improvement process comprises investment in recruiting and training our professionals, in modernizing and expanding our technological facilities and increasing our ability to process exams in our central laboratories. We highlight that, in the 2Q15, the Company acquired, for CDPI brand, the *Magnetom Prima 3 Tesla* Magnetic Resonance, the first advanced 3 Tesla Magnetic Resonance equipment in Latin America, which allows the processing of more detailed images and is used in advanced applications and state-of-the art research. The *Aquilion Prime* 160 channels Computerized Tomography was also acquired for Delboni brand, with one of the most advanced technologies in the world, which reduces the examination time and radiation dose to patients.

#### Gross Operating Revenue

The Company's consolidated gross revenue for the 2Q15 totaled R\$815.0 million, up 9.6% compared to 2Q14. In the first half of 2015, gross revenue amounted to R\$1,565.5 million, up 6.0% compared to the same period in 2014, in which gross revenue totaled R\$1,476.9 million.

Analyzing the Company's gross revenue by service line, the Lab-to-lab market (service of processing exams for third-party laboratories) was the one with the best performance in the quarter, with revenue of R\$95.9 million, a 17.5% increase compared to the 2Q14, representing 11.8% of the Company's total revenue. In the first half of 2015, revenue amounted to R\$184.3 million, up 14.7% compared to the same period in 2014, representing 11.8% of the Company's total revenue.

The outpatient market earned R\$591.8 million, an 8.3% growth compared to the 2Q14, totaling 72.6% of the Company's total revenue. In the first half of 2015, revenue amounted to R\$1,142.8 million, up 5.2% compared to the same period in 2014, representing 73.0% of the Company's total revenue.

The hospital market earned revenue of R\$81.4 million, performing a 13.5% increase compared to the 2Q14, thus representing 10.0% of the Company's total revenue. In the first half of 2015, revenue amounted to R\$152.3 million, up 9.2% compared to the same period in 2014, representing 9.7% of the Company's total revenue.

The public market earned revenues of R\$45.9 million with a 3.9% increase in the 2Q15, thus accounting for 5.6% of the Company's total revenue. In the first half of 2015, revenue amounted to R\$86.1 million, down 5.1% compared to the same period in 2014, representing 5.5% of the Company's total revenue.

## Notes to quarterly information

### Costs and Gross profit

In the second quarter of 2015, the costs of services rendered totaled R\$518.4 million, corresponding to 71.3% of net revenue, an increase of 9.9% compared to costs for the second quarter of 2014. Gross profit amounted to R\$208.3 million, down 3.4% compared to the same prior year period.

In the first half of 2015, the costs of services rendered totaled R\$992.6 million, corresponding to 71.8% of net revenue, an increase of 7.4% compared to the same prior year period. Gross profit amounted to R\$389.9 million, down 8.4% compared to the same prior year period.

### Operating Expenses

Operating expenses totaled R\$160.1 million in the 2Q15, representing 22.0% of net revenue. Compared to the 2Q14, there was a 14.2% increase. In the first half of 2015, the costs of operating expenses totaled R\$319.8 million, corresponding to 23.1% of net revenue, an increase of 12.6% compared to the same prior year period.

### EBITDA

EBITDA for the 2Q15 amounted to R\$93.2 million, down 19.0% compared to R\$115.0 million in the same prior year period. For this quarter, we reached a margin of 12.8% when compared with the 16.7% margin of the fourth quarter of last year.

EBITDA for the first half of 2015 amounted to R\$158.6 million, down 30.3% compared to R\$227.6 million in the same prior year period. This amount includes the operations of the first three months of companies Pro-Echo Cardiotada Serviços Médicos Ltda. and Lafê Serviços Diagnósticos Ltda., which were sold on April 1 and accounted for under the equity method.

In millions of reais	2Q14	2Q15	Δ%	YTD 2014	YTD 2015	Δ%
Net income for the period	31.9	11.5	-64%	60.5	10,2	-83,2%
(+) Income and social contribution taxes	15.1	11.0	-27,6%	28.1	11,5	-59,1%
(+) Net financial expenses	28.4	25,8	-9,3%	53.1	48,5	-8,6%
(+) Depreciation and amortization	39.6	45,0	13,6%	85.9	88,4	2,9%
<b>EBITDA (R\$ MM)</b>	<b>115.0</b>	<b>93,2</b>	<b>-19,0%</b>	<b>227.6</b>	<b>158,6</b>	<b>-30,3%</b>
<b>Ebitda margin</b>	<b>16.7%</b>	<b>12,8%</b>	<b>-3.9 p.a</b>	<b>16.9%</b>	<b>11,5%</b>	<b>-5,4 p.a</b>

	Six-month period ended 06/30/15	Second quarter 2015	Six-month period ended 06/30/14	Second quarter 2014
In thousands of R\$				
Income before income taxes	21,666	22,436		46,991
<b>Adjustments:</b>				
Depreciation and amortization (cost)	59,914		30,688	26,099
Depreciation and amortization (general and administrative expenses)	28,503		14,273	13,493
Financial income (expenses)	48,509		25,764	28,411
<b>EBITDA</b>	<b>158,593</b>		<b>93,160</b>	<b>114,994</b>

### Financial income (expenses)

Net financial expenses for 2Q15 amounted to R\$25.8 million, compared to R\$28.4 million in 2Q14, down 9.3%. In the first half of 2015, net financial expenses amounted to R\$48.5 million, compared to R\$53.1 million in the same prior year period, down 8.6%.

## Notes to quarterly information

### Income and Social Contribution Taxes

The income and social contribution taxes line totaled R\$11.0 million for the quarter against R\$15.1 million in the second quarter of last year. In the first half of 2015, the taxes line totaled R\$11.5 million against R\$28.1 million in the same prior year period.

### Net Income

Net income for the quarter amounted to R\$9.8 million, compared to net income of R\$31.9 million for the same prior year quarter. In the first half of 2015, net income amounted to R\$10.2 million, compared to R\$60.5 million for the same prior year period.

### Cash and short-term investments

Cash and highly-liquid short-term investments at quarter end totaled R\$623.9 million, which will be used to ensure expansion and modernization of existing units, opening of new units, the replacement of imaging equipment, further investments to improve quality, as well as the payment of dividends and debentures.

### Investments

Net CAPEX investments in the 2Q15 totaled R\$68 million. In the first half of 2015, net CAPEX investments totaled R\$109.8 million. Investments in this quarter were mainly destined to: (i) implementation and development of production and care systems and renewal of the technological facilities, (ii) refurbishment and expansion of existing service units and new units, and (iii) purchase of imaging equipment.

### Indebtedness

The Company's net debt totaled R\$811.3 million in 2Q15. Of gross indebtedness, 66.5% are recorded under the noncurrent portion and 6.7% refer to debts denominated in foreign currency. Net debt in foreign currency mainly comprises bank loan and equipment financing. The Company has short-term investments abroad, with the objective of providing hedge for the amount of loan and financing denominated in US dollar. The debts in Brazilian real are mostly relate to debentures.

### Significant events in the quarter

#### Fulfillment of condition for disposal - Pro-Echo and Lafê

On April 1, 2015, the Company communicated that the condition for the disposal to Newscan Serviços Médicos Ltda. of the units of interest representing, directly and indirectly, 100% of capital of Pro-Echo Cardiodata Serviços Médicos Ltda. and Lafê Serviços Diagnósticos Ltda. had been fulfilled, since the referred to operation was approved by Brazil's Administrative Council for Economic Defense ("CADE") and, conclusion thereof, represents fulfillment of one more stage of the Performance Commitment Agreement (PCA) entered into by the Company with CADE on December 4, 2013.

#### Election of Board of Directors' Member - Annual and Special Shareholders' Meeting in 2015

The Company's Annual and Special Shareholders' Meeting held on April 23, 2015, approved, without qualification and by majority voting, the group of candidates presented on March 23, 2015 by the controlling shareholders, with the consequent election of the Board of Director's members, indicated by them, namely: Romeu Côrtes Domingues, as Board of Directors' Chairman; Oscar de Paula Bernardes Neto, as Board of Directors' Vice Chairman; Marcelo Noll Barboza, as Board of Directors' member; Henrique Jäger, as Board of Directors' member; and Alexandre Barros, as Board of Directors' member.

## Notes to quarterly information

Board of Directors' members Oscar de Paula Bernardes Neto, Henrique Jäger and Alexandre de Barros are considered independent Board of Directors' members on the terms of the New Market Listing Regulation.

### Public Offering of Shares for purposes of exit from the New Market - Cromossomo Participações II S.A.

On April 27, 2015, the Company made public that received on said date a correspondence from Cromossomo Participações II S.A., its controlling shareholder, about Offerer's intention of making a voluntary public offering for the acquisition of up to 100% of common shares issued by DASA, held by DASA's noncontrolling shareholders, for purposes of exit of DASA from the special securities trading segment denominated New Market of BM&FBOVESPA S.A. Bolsa de Valores, Mercadorias e Futuros, without cancellation of the Company's registration with the Brazilian Securities and Exchange Commission (CVM) as issuer of securities class "A", on the terms of CVM Ruling No. 480, dated December 7, 2009, as amended.

## Significant subsequent events

### Valuation report

On July 8, 2015, the Company announced it had received on that date the valuation report on the Company's common shares, which was prepared by Itaú BBA S.A., as approved at the Special Shareholders' Meeting held on June 8, 2015.

According to the Valuation Report, Itaú BBA S.A. determined the economic value of the Company's common shares in the range between R\$10.32 and R\$11.35.

On July 20, 2015, the Company announced it had received an official letter from BM&FBOVESPA S.A. - Bolsa de Valores, Mercadorias e Futuros, relating to the aforementioned valuation report. The Company has already taken the measures requested in such official letter, and sent a copy thereof to Itaú BBA S.A., to the offered and to the intermediary institution in the scope of the public offering of shares.

### Second Stock Option Program

On July 10, 2015, the Company announced its Board of Directors had approved at a meeting held on that same date, the transfer of 140,425 treasury shares, in private transactions, representing 0.0450365% of the Company's capital to the beneficiaries of its Second Stock Option Program ("Second Program"), approved at the Board of Directors' Meeting held on April 24, 2012 and established in the scope of the Stock Option Plan approved by the Special Shareholders' Meeting held on January 5, 2011, due to the exercise of options within the Second Program.

### Cromossomo Participações II S.A. Correspondence - Reply to CVM Official Memorandum Circular

On July 24, 2015, the Company announced it had received a correspondence from Cromossomo Participações II S.A., related to their reply to the Official Memorandum No. 169/2015/CVM/SEP/GEA-4, in which Cromossomo Participações II S.A. clarifies that the shares issued by the Company will be listed in the traditional trading segment of BM&FBOVESPA if the exit from the New Market is carried forward, and explains the reasons why this decision is understood to be in accordance with the Company's social interests and serves loyally the rights and interests of all its shareholders. The entire correspondence can be found in the material news release disclosed by the Company on July 24, available on the Investor Relations website ([www.dasa3.com.br](http://www.dasa3.com.br)).



## **Notes to quarterly information**

### **Non-Accounting Projections and Data**

The representations in this document related to business prospects, projections of operating and financial results and those related to the Company's growth prospects are simple projections and, as such, are exclusively based on management's expectations about future business. This report on the Company's financial performance includes non-accounting, accounting as well as operating and financial data and projections based on Company management's expectations. Non-accounting data, excepting for EBITDA, were not subject matter of review by the Company's independent auditors.

### **Executive Board Representation**

Pursuant to the provisions in CVM Ruling No. 480, we represent hereby that we discussed, revised and agreed with the financial statements and also with the independent auditor's report on the corresponding quarterly information for the six-month period ended June 30, 2015.

### **Acknowledgments**

We would like to thank hereby our employees for their alignment, dedication and talent that allowed us to attain promising results, as well as our customers and shareholders, for their trust in us.

## Notes to quarterly information

### 1. Operations

Diagnósticos da América S/A (Company), headquartered in the city of Barueri, São Paulo State, is a publicly-held corporation with its registration granted by the Brazilian Securities and Exchange Commission (CVM) on November 5, 2004 for the trading of its securities on the stock market, having been listed in the Novo Mercado (New Market) segment of the São Paulo Stock Exchange (Bovespa) since November 19, 2004, under ticker DASA3.

The Company's business purpose is to render auxiliary diagnostic support services (SAD) either directly to individuals or through health insurance plans, insurance companies, medical-hospital assistance entities, other entities for healthcare financing, including clinical analysis and vaccination, either directly or as a supplementary service, through engaged laboratories; as well as other auxiliary diagnostic support services (SAD), exclusively through specialized clinics, such as in the following areas: a) cytology and pathologic anatomy; b) diagnostic by imaging and graphic methods; and c) nuclear medicine.

In addition, the Company is engaged in activities related to: (i) tests in food and substances for the purpose of evaluating risks for the human being; (ii) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general; (iii) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written media intended to promote scientific research or activities developed by the Company; (iv) granting and management of business franchising, which comprises funds for advertising and promotion, training and selection of employees, suggestion of equipment suppliers and research material, among others.

The Company also holds equity interest in other entities, either business related or not, an owner, member or shareholder.

## Notes to quarterly information

At the end of the first half of 2015, the Company had 505 outpatient and hospital units:

Brands	State	06/30/15	12/31/14
Delboni Auriemo (i)	São Paulo	42	43
Lavoisier	São Paulo	94	86
Bronstein	Rio de Janeiro	42	41
Lâmina (i)	Rio de Janeiro	15	16
Pasteur	Brasília	26	25
Frischmann	Paraná	35	34
Image	Bahia	4	4
Laboratório Álvaro	Paraná	13	14
LabPasteur	Ceará	17	18
Vita-Lâmina	Santa Catarina	2	2
Atalaia	Goias	22	22
Exame	Brasília	21	20
MedImagem	Rio de Janeiro	7	7
DASA (ii)	Rio Grande do Sul	2	3
Cedic/Cedilab	Mato Grosso	10	10
Unimagem	Ceará	1	1
CERPE	Pernambuco	37	39
Sérgio Franco	Rio de Janeiro	62	63
Multi Imagem	Rio de Janeiro	6	6
CDPI	Rio de Janeiro	7	7
Previlab	São Paulo	22	21
Cytolab	São Paulo	14	15
Alta Excelência Diagnóstica - Premium	São Paulo and Rio de Janeiro	4	3
		<b>505</b>	<b>500</b>

### Brands sold (see Note 13):

Sérgio Franco - Lafê	Rio de Janeiro	-	18
Proecho	Rio de Janeiro	-	14
		<b>505</b>	<b>532</b>

(i) At June 30, 2015, the brand Club DA had 23 units, 19 of them associated with the brand Delboni Auriemo and 4 units to brand Lâmina.

(ii) The Company's business unit operating in Mãe de Deus Hospital.

In addition, CientificaLab operates in the public healthcare sector, and the revenue therefrom arises from agreements entered into with customers in this sector. At the end of the first half of 2015, this operation recorded 35 customers, with exam requisitions totaling 3.4 million. CientificaLab has 686 collection units, 73 of them are hospitals and 613 are outpatient clinics not related to the units listed above.

The information above is not within the work scope of the independent auditor's review.

## 2. Performance Commitment Agreement ("PCA")

At the trial session held on December 4, 2013, Merger Review Process No. 08012.010038/2010 was approved by CADE Administrative Court, under the terms of Reporting Member, with restrictions negotiated with the Company and formalized by means of the Performance Commitment Agreement ("PCA").

With the execution of the PCA, the Transaction Reversibility Preservation Agreement ("APRO") executed by the Company on October 26, 2011, CADE considered this as completed, extinct and replaced by the PCA, as it accomplished the objective of preserving the transaction reversibility nature.

## Notes to quarterly information

### Restrictions provided for in the PCA are as follows

- (i) the Company shall dispose assets in the cities located in the state of Rio de Janeiro, jointly totaling R\$110,000 of the revenue for the year for a single acquiring third party which (a) has no direct or indirect relationship with the Company; and (b) does not have more than 20% (twenty percent) of the relevant market of Medical Diagnosis Services (“MDS”) in the city of Rio de Janeiro;
- (ii) The Company, for the initial term of 3 (three) years, cannot conduct the operations described in items (A) to (C) below, involving MDS service providers in the cities of Duque de Caxias, Nilópolis, Niterói, Nova Iguaçu, Rio de Janeiro, São Gonçalo and Belford Roxo, in the relevant markets of: (a) clinical analysis; (b) pathology and cytopathology; (c) echocardiogram, echocardiography, doppler, echo vascular, carotid and vertebral echo, transesophageal echo; (d) EEG; (e) CT scan; (f) ultrasonography; (g) MRI; (h) bone densitometry; and (i) mammogram:
  - (a) Merger or acquisition of company operating in the MDS market (“merger/acquisition”);
  - (b) Direct or indirect acquisition, by purchase or exchange of shares, units of interest or securities convertible into shares, or tangible or intangible assets through contract or by any other mean, of the control or portion of one or more companies operating in the MDS market (“Acquisition”); or
  - (c) Execution of an association contract, consortium or joint venture with companies in the MDS market (“Association” and, together with merger/acquisition transactions, as defined above, “Qualifying Operations”).
- (iii) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Guarulhos, Osasco, Santo André, São Bernardo do Campo, São Caetano do Sul, São Paulo and Taboão da Serra, in relevant markets of: (a) clinical analysis; (b) anatomy, pathology and cytopathology; (c) echocardiogram, echocardiography, Doppler, echo vascular, carotid and vertebral echo, transesophageal echo; (d) CT scan; (e) MRI; and (f) ultrasonography;
- (iv) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Curitiba and São José dos Pinhais, in relevant markets of: (a) clinical analysis, (b) CT scan, and (c) ultrasonography;
- (v) after the initial three-year or two-year term, as the case may be, as determined in items (ii), (iii) and (iv) above, respectively, and for the additional term of two years after the initial term, the Company shall submit any Qualifying Operations to prior approval from CADE in the respective locations, even if the minimum billing standards provided by competition law for mandatory notification of merger procedures are not reached.

Subject to the restrictions described above, the PCA a) does not hinder the corporate restructuring of Company or any of its subsidiaries, either directly or indirectly; b) does not hinder acquisition of companies outside the cities mentioned above; and c) does not have provisions that may hinder the Company’s organic growth.

### Notes to quarterly information

The Company management has taken the necessary measures to comply with the PCA obligations on a timely basis, and CADE's plenary session issued, on February 11, 2015, a decision approving the statement of partial compliance with the divestiture obligation under the PCA of the Merger Review Process DASA/MD1. The decision on partial compliance is due to the Company's obligation of gathering certain additional documents, which have already been submitted to CADE, which ultimately attested to the full compliance with the divestiture forecast in the PCA in an ordinary judgment session of March 25, 2015.

### 3. Consolidation procedures

The consolidated quarterly information includes the following financial information of Company and its subsidiaries:

Direct subsidiaries		Interest	06/30/15	12/31/14
Cientificalab Produtos Laboratoriais e Sistemas Ltda.	Diagnósticos da América S.A.		<b>88.30%</b>	82.90%
	DASA Real Estate Empreendimentos Imobiliários Ltda.		<b>11.70%</b>	17.10%
Dasa Finance Corporation	Diagnósticos da América S.A.		<b>100.00%</b>	100.00%
Dasa Real Estate Empreendimentos Imobiliários Ltda.	Diagnósticos da América S.A.		<b>99.99%</b>	99.99%
	Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda.		<b>0.01%</b>	0.01%
Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda.	Diagnósticos da América S.A.		<b>99.00%</b>	99.00%
	Dr. Luciano Flávio Freitas de Almeida		<b>1.00%</b>	1.00%
Dasa Property Participações Ltda.	Diagnósticos da América S.A.		<b>99.00%</b>	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.		<b>1.00%</b>	1.00%
Previlab Análises Clínicas Ltda.	Diagnósticos da América S.A.		<b>99.65%</b>	99.65%
	Alcione Moya Aprilante		<b>0.31%</b>	0.31%
	César Antônio Blázio		<b>0.04%</b>	0.04%
Pro Echo Cardiodata Serviços Médicos Ltda. (a)	Diagnósticos da América S.A.		-	100.00%
LAFÊ Serviços Diagnósticos Ltda. (a)	Diagnósticos da América S.A.		-	99.99%
	Pro Echo Cardiodata Serviços Médicos Ltda.		-	0.01%
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	Diagnósticos da América S.A.		<b>70.00%</b>	70.00%
	José Antonio Fragoso Borges Filho		<b>15.00%</b>	15.00%
	José Carlos de Castro Bersot		<b>7.50%</b>	7.50%
	Eduardo Luiz Primo de Siqueira		<b>7.50%</b>	7.50%
Check Up UP - Unidade Preventiva, Diagnóstico e Medicina Preventiva Ltda.	Diagnósticos da América S.A.		<b>99.99%</b>	99.99%
	DASA Real Estate Empreendimentos Imobiliários Ltda.		<b>0.01%</b>	0.01%
Indirect subsidiaries		Interest	06/30/15	12/31/14
Stat Análises Clínicas Ltda.	Previlab Análises Clínicas Ltda.		<b>99.66%</b>	99.66%
	Alcione Moya Aprilante		<b>0.17%</b>	0.17%
	César Antônio Blázio Sanches		<b>0.17%</b>	0.17%

(a) On April 1, 2015, the Company completed the transaction to dispose of 100% of Pro-Echo Cardiodata Serviços Médicos Ltda.'s and Lafê Serviços Diagnósticos Ltda.' capital. Please refer to Note 13.

## Notes to quarterly information

### 4. Basis of preparation

#### 4.1. Statement of compliance (with respect to IFRS and CPC standards)

The quarterly information includes the individual and consolidated quarterly information prepared in accordance with Technical Pronouncement CPC 21 (R1), and in accordance with IAS 34 – Interim Financial Reporting issued by the International Accounting Standards Board (IASB) and presented in accordance with the Brazilian SEC rules.

The issue of the individual and consolidated quarterly information was authorized by the Board of Directors in a meeting held on August 10, 2015.

#### 4.2. Basis of measurement

The individual and consolidated quarterly information was prepared considering the historical cost, except for the following items recognized in the balance sheets: (i) derivative financial instruments measured at fair value; and (ii) non-derivative financial instruments measured at fair value thought profit or loss.

#### 4.3. Functional and reporting currency

The individual and consolidated quarterly information is presented in Real (R\$), which is the Company's functional currency. All financial information presented in Real was rounded to the nearest thousand, unless otherwise stated.

#### 4.4. Use of estimates and judgments

The preparation of individual and consolidated quarterly information in accordance with the IFRS and accounting practices adopted in Brazil requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported asset, liability, revenue and expense amounts. Actual results may differ from these estimates.

Estimates and assumptions are permanently reviewed. The reviews, with respect to accounting estimates, are recognized in the period when estimates are reviewed and for any future periods affected.

Uncertainties about the assumptions or estimates that may pose significant risk of material adjustment in future periods are detailed in the following notes:

- Note 5.8 (12/31/14) - Impairment - key assumptions used in discounted cash flow estimates used for calculation of goodwill impairment;
- Note 10 - Trade accounts receivable - analysis of allowance for doubtful accounts considering disallowed amounts, default levels and returned checks;
- Note 20 - Provisions for tax, social security, civil and labor contingencies;
- Note 22 - Income and social contribution taxes - analysis of the recovery of deferred taxes; and
- Note 25 - Assumptions used to determine fair value of financial instruments.

## Notes to quarterly information

### 4.5. Segregation between current and noncurrent

Except for deferred taxes, the Company has segregated balance sheet items into current, when such items are expected to be realized within twelve months after the quarterly information date.

### 4.6. Statement of comprehensive income

There were no equity transactions that could cause adjustments in the statement of comprehensive income, i.e. income for the year is equal to the comprehensive income.

## 5. Significant accounting policies

The Company declares that the Quarterly Information (ITR) is presented in accordance with the accounting practices set out in Note 5 to financial statements for the year ended December 31, 2014.

## 6. Pronouncements of IFRS, CPC and new legal requirements

New pronouncements not yet in force, which will go into effect as from the business year beginning January 1, 2015 for items i) and ii), January 1, 2016 for item iii), and January 1, 2017 for item iv).

- i) IFRS 9 - Financial Instruments - reflects the first phase of the IASB initiatives to supersede IAS 39 and applies to the classification and evaluation of financial assets and liabilities, pursuant to IAS 39. The pronouncement would be initially applied for years beginning January 1, 2013 or thereafter, however Amendments to IFRS 9 Mandatory Effective Date of IFRS 9 and Transition Disclosures, issued in December 2011, postponed its effectiveness to January 1, 2015. Later on, the IASB will approach issues such as accounting for hedges and provision for losses on financial assets. The Company does not expect this standard to have significant effects on its financial statements.
- ii) IFRS 21 - Levies - tax obligations shall only be recognized when the event giving rise to such obligation takes place. The Company is assessing the impacts on its interim financial statements from adopting this pronouncement.
- iii) IAS 16 and IAS 38 - Clarification on Reasonable Depreciation and Amortization Methods - The amendments shed light into the principle outlined in IAS 16 and IAS 38, i.e. that revenue reflects a model of economic benefits generated by a business operation (of which the asset is an integral part), instead of the economic benefits consumed through the use of the asset. Thus, a revenue-based method cannot be used to depreciate PP&E, but only under very limited circumstances to amortize intangible assets. The amendments are in force prospectively to amortize intangible assets. These amendments are prospectively effective for annual periods beginning on or after January 1, 2016. These amendments are not expected to have any impact on the Group, since the Company did not use any revenue-based method to depreciate noncurrent assets.
- iv) IFRS 15 - Revenue from Contracts with Customers: introduces a five-step model applicable to revenue from contracts with customers, irrespective of the type of revenue transaction or industry. It applies to all revenue contracts and provides a model for recognition and measurement of gains or losses on the sale of some non-financial assets not related to an entity's ordinary activities (e.g. sales of real estate, premises and equipment or intangible assets). Extensive disclosures are also required for this standard. This pronouncement shall be applied for annual periods beginning January 1, 2018 or thereafter. The Company is assessing the impacts on its interim financial statements from the adoption of this pronouncement.

## Notes to quarterly information

The improvements and amendments in the following pronouncements: IFRS 11 - Joint Agreements; IFRS 14 - Regulatory Deferral Accounts and Amendments to IAS 41 - Biological Assets and Agricultural Products had not effects on the Company.

There are no further IFRS standards which have not gone into effect but might have a significant impact on the Company.

### 7. Determination of fair value

A number of the Company's accounting policies and disclosures require the determination of fair value, for financial and non-financial assets and liabilities. The fair values have been calculated for the purpose of measurement and/or disclosure based on the methods stated below. Where applicable, further information about the assumptions used in determining fair values is disclosed in the notes specific to that asset or liability.

#### 7.1. Property and equipment

The fair value of property and equipment recognized as a result of a business combination is based on market values. The market value of property and equipment is the estimated amount at which an asset could be exchanged on the date of valuation between knowledgeable and interested parties in a transaction on an arms' length basis. The fair value of items of property and equipment is based on market and cost approaches through market prices quoted for similar items, when available, and replacement cost when appropriate.

For finance leases, the interest rate is determined by reference to similar lease contracts.

#### 7.2. Intangible assets

The fair value of trademarks and patents acquired in a business combination is based on the present value of estimated royalty payments that were avoided as a result of the ownership of the trademark or patent. The fair value of customer relationships acquired in a business combination is determined using the multi-period excess earnings method (MEEM), whereby the underlying asset is valued after deducting a fair return on all other assets that integrate the generation of their respective cash flows.

#### 7.3. Derivatives

The fair value of interest rate swap contracts is determined for disclosure purposes through discount of estimated future cash flows based on conditions and maturity of each contract, using market interest rate for similar instruments at measurement date. Fair values reflect the credit risk of the instrument and include adjustments to consider the credit risk of the Group's entity and of the counterparty, when appropriate.



## Notes to quarterly information

### 7.4. Non-derivative financial liabilities

The fair value determined for disclosure purposes is calculated based on the present value of the principal and of future cash flows, discounted at the market interest rate determined at the date of the interim financial statements. As to the liability component of convertible debt instruments, the market interest rate is determined by reference to similar liabilities that do not have a conversion option.

### 7.5. Share-based payment transactions

The fair value of employee share-based payments and the share appreciation rights are measured based on the market price per share (BMF&Bovespa quotation) in proportion to the number of shares and to the days elapsed between the date of the beneficiary election to the plan and the date of the financial statements.

## 8. Cash and cash equivalents

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
Cash and banks	17,945	17,123	64,413	20,059
Short-term investments	283,154	223,144	298,394	254,927
	<b>301,099</b>	240,267	<b>362,807</b>	274,986

Cash and cash equivalents classified in consolidated current assets are presented below:

	06/30/15		12/31/14	
	Amount	Average yield for the period	Amount	Average yield for the period
Cash and banks	64,413	-	20,059	-
Bank Deposit Certificate (CDB) / Repurchase agreements	118,222	99.86% of CDI <sup>1</sup>	115,478	101.84% of CDI
Fixed income fund	180,172	101.01% of CDI	139,449	101.20% of CDI
	<b>362,807</b>		<b>274,986</b>	

Bank deposits represent balances in banks and immediate liquidity rights, the use of which is not subject to any restrictions.

Short-term investments are readily redeemable from the issuer into a known cash amount and are subject to insignificant risk of change in value.

<sup>1</sup> Interbank Deposit Certificate (CDI).

**Notes to quarterly information****9. Marketable securities**

	Company				
	Currency	06/30/15		12/31/14	
		Amount in R\$	Average yield for the period	Amount in R\$	Average yield for the period
Bank Deposit Certificate (CDB) / Repurchase agreements (a)	R\$	105,817	103.42% of CDI	8,865	100.01% of CDI
Fixed income fund (a)	R\$	64,112	106.21% of CDI	58,236	105.55% of CDI
		<u>169,929</u>		<u>67,101</u>	
Current assets		<u>(58,585)</u>		<u>(51,674)</u>	
Noncurrent assets		<u>111,344</u>		<u>15,427</u>	

	Consolidated						
	Currency	06/30/15			12/31/14		Average yield for the period
		Amount in US\$	Amount in R\$	Average yield for the period	Amount in US\$	Amount in R\$	
Bank Deposit Certificate (CDB) / Repurchase agreements (a)	R\$	-	105,817	103.42% of CDI	-	8,865	100.01% of CDI
Fixed income fund (a)	R\$	-	117,001	106.13% of CDI	-	97,524	105.39% of CDI
Corporate bonds (b)	US\$	18,329	56,869	5.16% p.a.	31,777	84,405	4.99% p.a.
		-	<u>279,687</u>		-	<u>190,794</u>	
Current assets		-	<u>(157,704)</u>		-	<u>(165,239)</u>	
Noncurrent assets		-	<u>121,983</u>		-	<u>25,555</u>	

(a) Of the amount of consolidated noncurrent marketable securities, R\$18,596 (R\$25,555 at December 31, 2014) was invested in fixed income funds and CDB / Repurchase agreements corresponds to guarantee for payment of contingencies that may be demanded from acquired companies, for a period of up to 6 years from the date of acquisition.

(b) Government securities and corporate bonds acquired by foreign subsidiary.

**10. Trade accounts receivable**

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
Trade notes receivable:				
Falling due	369,159	403,587	379,821	421,796
Overdue (b)	187,797	133,484	232,527	173,653
	<u>556,956</u>	<u>537,071</u>	<u>612,348</u>	<u>595,449</u>
Other accounts receivable				
Checks receivable	317	320	321	330
Returned checks	1,526	1,445	1,543	1,458
Credit card	19,170	12,425	19,927	13,033
Unbilled health plans (a)	92,746	63,606	120,854	80,941
	<u>113,759</u>	<u>77,796</u>	<u>142,645</u>	<u>95,762</u>
Total receivable	<u>670,715</u>	<u>614,867</u>	<u>754,993</u>	<u>691,211</u>

**Notes to quarterly information**

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
Less				
Allowance for doubtful accounts due to disallowance, default and returned checks	(61,808)	(44,366)	(85,229)	(60,819)
Adjustment to present value	-	-	-	(886)
	<b>608,907</b>	570,501	<b>669,764</b>	629,506
Current assets	<b>(608,507)</b>	(569,943)	<b>(667,554)</b>	(626,721)
Noncurrent assets	<b>400</b>	558	<b>2,210</b>	2,785

(a) Refers to amounts of services rendered and not yet billed at period end. Services not billed within 120 days are written off from account unbilled health plans, adjusting the P&L for the period they occur.

(b) The aging of overdue balances is as follows:

	% of provision	Company					
		06/30/15			12/31/14		
		Gross amount	Provision for loss	Net amount	Gross amount	Provision for loss	Net amount
0 to 30		67,268	-	67,268	53,074	-	53,074
31 to 60		20,680	-	20,680	14,253	-	14,253
61 to 90		12,727	-	12,727	8,879	-	8,879
91 to 120	25%	9,317	(2,329)	6,988	7,342	(1,836)	5,506
121 to 180	50%	14,431	(7,216)	7,215	8,457	(4,229)	4,228
181 to 360	75%	50,548	(37,911)	12,637	18,491	(13,868)	4,623
Above 360	100%	12,826	(12,826)	-	22,988	(22,988)	-
		<b>187,797</b>	<b>(60,282)</b>	<b>127,515</b>	133,484	(42,921)	90,563
Returned checks		1,526	(1,526)	-	1,445	(1,445)	-
		<b>189,323</b>	<b>(61,808)</b>	<b>127,515</b>	134,929	(44,366)	90,563
Consolidated							
	% of provision	06/30/15			12/31/14		
		Gross amount	Provision for loss	Net amount	Gross amount	Provision for loss	Net amount
0 to 30		77,685	-	77,685	64,908	-	64,908
31 to 60		23,703	-	23,703	17,724	-	17,724
61 to 90		15,697	-	15,697	12,825	-	12,825
91 to 120	25%	12,620	(3,155)	9,465	8,561	(2,140)	6,421
121 to 180	50%	16,262	(8,131)	8,131	10,339	(5,170)	5,169
181 to 360	75%	56,642	(42,482)	14,160	28,982	(21,737)	7,245
Above 360	100%	29,918	(29,918)	-	30,314	(30,314)	-
		<b>232,527</b>	<b>(83,686)</b>	<b>148,841</b>	173,653	(59,361)	114,292
Returned checks		1,543	(1,543)	-	1,458	(1,458)	-
		<b>234,070</b>	<b>(85,229)</b>	<b>148,841</b>	175,111	(60,819)	114,292

## Notes to quarterly information

The collection process for diagnostic support services provided by the Company is complex due to a variety of factors, including the large number of health plans used and different coverage offered. This complexity has historically given rise to losses due to disallowances. On these terms, the Company sets up an allowance for doubtful accounts. When necessary, and in connection solely with the increase in the level of credit risk of some paying sources, the Company sets up a specific additional allowance for these customers.

Disallowances mainly refer to: (i) operating issues, such as services rendered to customers of health care plans without previous authorization; (ii) sales issues, such as new price lists agreed, which have not been updated on both systems; and (iii) technical issues, such as different interpretations of examination requisitions.

To cover the losses as a result of such disallowances and default, the Company adopts the policy of setting up an allowance for receivables overdue for more than 90 days, according to the table below:

<u>Overdue receivables</u>	<u>% of allowance</u>
91 to 120 days	25%
121 to 180 days	50%
181 to 360 days	75%
Above 360 days	100%

To allow absorption of losses from the increase in credit risk, the Company supplemented the allowance in relation to some customers in the private and public market by R\$32,000 in the first half of 2015, as their financial condition entails further difficulty to recover the respective credits. To the extent that the accrued accounts are settled, the Company will complete the related reversals.

In the first half of 2015 losses from disallowances and default stood at 2.4% of gross operating revenues (2.5% in the first half of 2014).

From 2012, the Company began to derecognize any receivables overdue for over 2 years against the allowance. In the first half of 2015, under this criterion R\$10,488 (R\$9,668 in the first half of 2014) was written off.

The Company also adopts the criterion of setting up an allowance for 100% of the checks returned due to non-sufficient funds.

Given that receivables from credit card companies are historically fully paid, the Company has not set up an allowance for losses in this account.

In the first half of 2015, changes in allowances for doubtful accounts due to disallowance, default and returned checks, in consolidated, are as follows:

Balance at December 31, 2014	-	<b>(60,819)</b>	
<b>Change in the consolidated allowance</b>			
Allowances for doubtful accounts due to disallowance and default	(52,568)		
Reversal of allowance for disallowance and default due to payment and proper disallowance	28,073	(24,495)	(a)
Allowance for returned checks	-	85	
Balance at June 30, 2015	-	<b>(85,229)</b>	

(a) Loss in the first half of 2015, as disclosed in Note 28.

## Notes to quarterly information

### 11. Inventories

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
Direct material - domestic	36,264	37,824	40,836	42,524
Direct material - imported	5,862	8,452	6,503	9,007
Secondary material - domestic	13,158	13,409	14,424	14,648
Supplies	6,617	6,285	7,254	6,913
Provision for loss and obsolescence (a)	(2,273)	(945)	(2,802)	(1,150)
	<b>59,628</b>	<b>65,025</b>	<b>66,215</b>	<b>71,942</b>

(a) To better reflect the Company's best loss estimate in relation to its inventories, the provision for obsolescence was set up for certain items that have not been moved for more than 180 days (120 days until December 31, 2014).

### 12. Taxes recoverable

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
Income and social contribution taxes (IR/CS) - withholding income tax on billing	41,500	1,197	43,846	2,157
IR/CS - prepayments for the period	849	-	1,758	-
IR/CS - credits recoverable	39,007	84,187	46,047	92,598
PIS/COFINS - withholding income tax on billing	32,547	28,456	34,402	29,883
ISS - withholding income tax on billing	2,243	7,470	7,542	13,983
INSS recoverable	7,045	7,874	29,666	29,635
Other	11,402	10,027	11,795	10,421
	<b>134,593</b>	<b>139,211</b>	<b>175,056</b>	<b>178,677</b>

### 13. Sale of investment

In 2014, as consequence of the decision given by Brazil's Administrative Council for Economic Defense ("CADE") dated December 4, 2013, within the scope of the merger review process referring to the acquisition of MD1 Diagnósticos S.A., the Company management has committed itself to sell assets in the cities of Rio de Janeiro State, totaling R\$110,000 of revenue per year, to a one single third party that (a) has no partnership relations (either directly or indirectly) with the Company; and (b) holds no more than 20% (twenty percent) of the relevant diagnostic support service market in the city of Rio de Janeiro.

The Board of Directors' meeting held on December 27, 2014 approved the disposal of units of interest representing, both directly and indirectly, 100% (one hundred percent) of the capital of Pro-Echo Cardiodata Serviços Médicos Ltda. ("ProEcho") and Lafê Serviços Diagnósticos Ltda. ("Lafê"), as well as all rights inherent thereto, for R\$66,000, the terms and other conditions being provided for in the Units of Interest Purchase and Sale Agreement entered into on December 27, 2014, between the Company, as the seller, Newscan Serviços Médicos Ltda., as the buyer, João Renato Côrtes de Barros Silveira, as the guarantor, ProEcho and Lafê, as the consenting intervening parties, under the terms negotiated by the Executive Board. The Board of Directors has authorized the members of the Executive Board to take all actions relating and supplementary to, or arising from the Purchase and Sale Agreement, or that are necessary to its completion, including before CADE, since it approved the operation.

**Notes to quarterly information**

The balance sheet on April 1, 2015, date of effective sale of discontinued operation, is broken down as follows:

a) Consolidated

	<b>Lafê</b>	<b>Pro Echo</b>	<b>Total</b>
	<b>04/01/15</b>	<b>04/01/15</b>	<b>04/01/15</b>
<b>Assets</b>			
Cash and cash equivalents	4,589	5,187	9,776
Trade accounts receivable	14,372	11,038	25,410
Recoverable and deferred taxes	2,735	12,727	15,462
Property and equipment	1,521	12,548	14,069
Intangible assets	385	133	518
Other receivables	253	651	904
	<b>23,855</b>	<b>42,284</b>	<b>66,139</b>
Goodwill in Company referring to acquisition of subsidiary Pro Echo	-	-	15,788
	<b>-</b>	<b>-</b>	<b>81,927</b>
<b>Assets</b>			
	<b>Lafê</b>	<b>Pro Echo</b>	<b>Total</b>
	<b>04/01/15</b>	<b>04/01/15</b>	<b>04/01/15</b>
<b>Liabilities</b>			
Trade accounts payable	(459)	(433)	(892)
Bank loans and financing	-	(35)	(35)
Salaries, social charges and vacation pay payable	(1,034)	(2,007)	(3,041)
Taxes and contributions payable	(2,951)	(411)	(3,362)
Specialized medical services payable	(1,592)	(1,908)	(3,500)
Provisions for tax, social security, civil and labor contingencies	-	(1,355)	(1,355)
Other accounts payable	(382)	(846)	(1,228)
	<b>(6,418)</b>	<b>(6,995)</b>	<b>(13,413)</b>
<b>Liabilities of discontinued operations</b>			

b) Company

	<b>Lafê</b>	<b>Pro Echo</b>	<b>Total</b>
	<b>04/01/15</b>	<b>04/01/15</b>	<b>04/01/15</b>
Net assets of subsidiaries held for sale	17,437	35,289	52,726
Goodwill in Company referring to acquisition of subsidiary Pro Echo	-	-	15,788
	<b>17,437</b>	<b>35,289</b>	<b>68,514</b>
<b>Investment held for sale (discontinued operation)</b>	<b>17,437</b>	<b>35,289</b>	<b>68,514</b>

The income statement for the period ended April 1, 2015 of Pro-Echo and Lafê, and the income statement for the period ended March 31, 2014 (updated) of Pro-Echo, are represented by the account discontinued operations in the Company's income statement. They break down as follows:

**Notes to quarterly information**

	<b>Lafê 04/01/15</b>	<b>Pro Echo 04/01/15</b>	<b>Total 04/01/15</b>	<b>Pro-Echo 03/31/14</b>
Net operating revenue	15,046	8,782	23,828	9,677
Cost of services rendered	(8,055)	(10,498)	(18,553)	(10,206)
Gross Profit (loss)	<u>6,991</u>	<u>(1,716)</u>	<u>5,275</u>	<u>(529)</u>
General and administrative expenses	(1,014)	(1,902)	(2,916)	(1,677)
Income (loss) before financial income (expenses) and taxes	<u>5,977</u>	<u>(3,618)</u>	<u>2,359</u>	<u>(2,206)</u>
Financial income	6	95	101	1,481
Income (loss) before income and social contribution taxes	<u>5,983</u>	<u>(3,523)</u>	<u>2,460</u>	<u>(725)</u>
Income and social contribution taxes	(2,028)	1,198	(830)	252
Net income (loss) for the period	<u>3,955</u>	<u>(2,325)</u>	<u>1,630</u>	<u>(473)</u>

The net cash flow statement for the period ended April 1, 2015 of Pro-Echo and Lafê breaks down as follows:

	<b>Lafê 04/01/15</b>	<b>Pro Echo 04/01/15</b>	<b>Total 04/01/15</b>
Operating activities	245	(220)	25
Investing activities	-	(389)	(389)
Financing activities	2,900	(511)	2,389
Net cash generated (used)	3,145	(1,120)	2,025

On April 1, 2015, the Company published a material news release communicating that the condition for the disposal to Newscan Serviços Médicos Ltda. of the units of interest representing, directly and indirectly, 100% of capital of Pro-Echo Cardiodata Serviços Médicos Ltda. and Lafê Serviços Diagnósticos Ltda. had been fulfilled, since the referred operation was approved by CADE and, conclusion thereof, represents fulfillment of one more stage of the Performance Commitment Agreement (PCA) entered into by the Company with CADE on December 4, 2013 (see Note 2). Considering the fulfillment of the condition for the disposal, on April 1, 2015, the Commitment Agreement was executed, with a sale amount of R\$66,000, whose terms and other conditions are provided for in the Units of Interest Purchase and Sale Agreement entered into on December 27, 2014. Upon write-off of assets that represented the interest held in the companies disposed of, loss amounting to R\$2,515 was recognized in P&L for the period, under "Other operating expenses". At June 30, 2015, the balance of accounts receivable for the sale of ownership interest amounts to R\$64,764 duly updated by reference to the accumulated variation of the Extended Consumer Price Index (IPC-A) since December 27, 2014, date of the units of interest purchase and sale agreement.

## Notes to quarterly information

### 14. Investments

#### 14.1. Information on investments in subsidiary

	Company		Consolidated	
	06/30/15	12/31/14	06/30/15	12/31/14
DASA Real Estate Empreendimentos Imobiliários Ltda.	25,799	26,420	-	-
CientíficaLab Produtos Laboratoriais e Sistemas Ltda.	153,353	100,389	-	-
Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE)	41,025	38,433	-	-
Previlab - Análises Clínicas Ltda.	32,484	32,262	-	-
Dasa Finance Corporation	8,287	4,719	-	-
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	1,761	2,031	-	-
Dasa Property Participações Ltda.	54	53	-	-
	<b>262,763</b>	<b>204,307</b>	<b>-</b>	<b>-</b>
Other investments	399	679	529	803
	<b>263,162</b>	<b>204,986</b>	<b>529</b>	<b>803</b>

Subsidiaries	Reporting date	Number of units of interest/shares	Number of shares/units of interest held	Interest in paid-in capital (%)	Paid-in capital	Equity	Net income (loss) for the period
DASA Real Estate	06/30/2015	25,667,079	25,667,078	99.99	25,667	25,799	(1,225)
	12/31/2014	25,667,079	25,667,078	99.99	25,667	27,420	(2,963)
CientíficaLab	06/30/2015	158,176,628	139,676,628	88.30	158,177	153,353	(7,432)
	12/31/2014	108,176,629	89,676,628	82.90	97,177	99,785	(11,196)
DASA Finance Corp	06/30/2015	18,550,000	18,550,000	100.00	41,123	8,287	3,568
	12/31/2014	18,550,000	18,550,000	100.00	41,123	4,719	1,924
CERPE	06/30/2015	122,024	120,804	99.00	122	41,025	4,428
	12/31/2014	122,024	120,804	99.00	122	38,433	6,047
Pro Echo (a)	06/30/2015	47,483,058	47,483,058	100.00	-	-	(2,325)
	12/31/2014	47,483,058	47,483,058	100.00	47,483	-	(5,249)
Previlab	06/30/2015	29,613,314	29,509,743	99.56	29,613	32,484	663
	12/31/2014	29,613,314	29,509,743	99.56	29,613	32,262	237
CRMI Petrópolis	06/30/2015	1,080,222	756,155	70.00	1,080	1,761	396
	12/31/2014	1,080,222	756,155	70.00	1,080	2,031	360
LAFÊ Serviços Diagnósticos Ltda. (a)	06/30/2015	6,376,316	6,376,216	99.99	-	-	3,955
	12/31/2014	6,376,316	6,376,216	99.99	10,376	-	207
Dasa Property Part.	06/30/2015	50,000	49,500	99.00	50	54	2
	12/31/2014	50,000	49,500	99.00	50	53	2
Check-UP Unidade Preventiva Ltda	06/30/2015	6,563,817	6,563,816	99.99	6,564	-	(1,715)
	12/31/2014	563,817	563,816	99.99	564	(4,459)	(710)

(a) On April 1, 2015, the Company completed the transaction to dispose of 100% of Pro-Echo Cardiodata Serviços Médicos Ltda.'s and Lafê Serviços Diagnósticos Ltda.' capital.



**Notes to quarterly information****14.2. Changes in investments**

	Balance at 12/31/14	Capital increase	Transfer from negative equity to investment	Proposed and prepaid dividends (a)	Interest on equity	Sales of investment (Note 13)	Equity pickup	Balance at 06/30/15
DASA Real Estate	27,024	-	-	-	-	-	(1,225)	25,799
CientificaLab	99,785	61,000	-	-	-	-	(7,432)	153,353
CERPE	38,433	-	-	(1,618)	(218)	-	4,428	41,025
Pro Echo	-	-	-	-	-	2,325	(2,325)	-
Previlab	32,262	-	-	(441)	-	-	663	32,484
Dasa Finance Corporation	4,719	-	-	-	-	-	3,568	8,287
CRMI Petrópolis	2,031	-	-	(666)	-	-	396	1,761
Lafê Serviços Diagnósticos	-	2,900	-	-	-	(6,855)	3,955	-
Dasa Property Part.	53	-	-	(1)	-	-	2	54
Check-up UP	-	6,000	(4,285)	-	-	-	(1,715)	-
	<b>204,307</b>	<b>69,900</b>	<b>(4,285)</b>	<b>(2,726)</b>	<b>(218)</b>	<b>(4,530)</b>	<b>315</b>	<b>262,763</b>
Check-up UP (negative equity)	(4,459)	-	4,285	-	-	-	-	(174)
	<b>199,848</b>	<b>69,900</b>	<b>-</b>	<b>(2,726)</b>	<b>(218)</b>	<b>(4,530)</b>	<b>315</b>	<b>262,589</b>

(a) Proposed and prepaid dividends

Dividends proposed in the amount of R\$458 for 2013; R\$2,064 referring to P&L determined in 2014; and prepaid dividends amounting to R\$204 for the first half of 2015.

**15. Property and equipment**

	Average depreciation rate % p.a.	Company			
		06/30/15		12/31/14	
		Cost	Accumulated depreciation	Net	Net
Properties	4	824	(549)	275	522
Leasehold improvements		513,968	(280,422)	233,546	229,506
Machinery and equipment	12	537,427	(244,608)	292,819	279,730
Furniture and fixtures	11	64,097	(25,924)	38,173	30,524
Facilities	10	72,287	(25,837)	46,450	42,768
IT equipment	20	114,632	(66,706)	47,926	45,136
Vehicles	20	4,018	(3,267)	751	785
Library	10	184	(135)	49	55
Land	-	255	-	255	255
Construction in progress	-	18,715	-	18,715	23,499
		<b>1,326,407</b>	<b>(647,448)</b>	<b>678,959</b>	<b>652,780</b>

**Notes to quarterly information**

	Average depreciation rate % p.a.	Consolidated			
		06/30/15		12/31/14	
		Cost	Accumulated depreciation	Net	Net
Properties	4	4,564	(1,841)	2,723	3,044
Leasehold improvements		532,806	(289,099)	243,707	238,573
Machinery and equipment	12	552,062	(253,457)	298,605	287,223
Furniture and fixtures	11	68,399	(27,905)	40,494	32,202
Facilities	10	74,025	(26,370)	47,655	43,829
IT equipment	20	118,995	(69,872)	49,123	46,750
Vehicles	20	5,208	(4,414)	794	842
Library	10	195	(144)	51	57
Land	-	7,135	-	7,135	7,135
Construction in progress	-	18,770	-	18,770	23,573
		<b>1,382,159</b>	<b>(673,102)</b>	<b>709,057</b>	<b>683,228</b>

Changes in cost

	Company				
	Change in the period				
	12/31/14	Additions	Write-offs	Transfers (a)	06/30/15
Properties	1,426	-	-	(602)	824
Leasehold improvements	489,198	14,343	(632)	11,059	513,968
Machinery and equipment	504,313	34,937	(7,255)	5,432	537,427
Furniture and fixtures	53,963	8,402	(1,182)	2,914	64,097
Facilities	65,251	3,042	(222)	4,216	72,287
IT equipment	104,262	10,476	(1,336)	1,230	114,632
Vehicles	3,990	90	(62)	-	4,018
Library	184	-	-	-	184
Land	255	-	-	-	255
Construction in progress	23,499	15,261	-	(20,045)	18,715
	<b>1,246,341</b>	<b>86,551</b>	<b>(10,689)</b>	<b>4,204</b>	<b>1,326,407</b>

	Consolidated					
	Change in the period					
	12/31/14	Additions	Write-offs	Transfers (a)	Sale of investment (b)	06/30/15
Properties	5,166	-	-	(602)	-	4,564
Leasehold improvements	506,201	16,607	(1,021)	11,059	(40)	532,806
Machinery and equipment	521,498	35,639	(10,160)	5,432	(347)	552,062
Furniture and fixtures	57,523	9,320	(1,358)	2,914	-	68,399
Facilities	66,780	3,308	(280)	4,217	-	74,025
IT equipment	109,063	10,566	(1,864)	1,230	-	118,995
Vehicles	5,445	89	(326)	-	-	5,208
Library	195	-	-	-	-	195
Land	7,135	-	-	-	-	7,135
Construction in progress	23,573	15,262	(19)	(20,046)	-	18,770
	<b>1,302,579</b>	<b>90,791</b>	<b>(15,028)</b>	<b>4,204</b>	<b>(387)</b>	<b>1,382,159</b>

(a) Expenses made by the Company classified under Construction in progress for the construction, installation and development period, which are transferred to a specific account of property and equipment or intangible assets when available for use.

(b) Changes in the period of discontinued operations, as mentioned in Note 13.

**Notes to quarterly information**Changes in accumulated depreciation

	<b>Company</b>				
	<b>Change in the period</b>				
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	<b>06/30/15</b>
Properties	(904)	(20)	-	375	<b>(549)</b>
Leasehold improvements	(259,692)	(20,500)	146	(376)	<b>(280,422)</b>
Machinery and equipment	(224,583)	(27,277)	6,925	327	<b>(244,608)</b>
Furniture and fixtures	(23,439)	(2,988)	526	(23)	<b>(25,924)</b>
Facilities	(22,483)	(3,361)	24	(17)	<b>(25,837)</b>
IT equipment	(59,126)	(8,377)	1,066	(269)	<b>(66,706)</b>
Vehicles	(3,205)	(124)	62	-	<b>(3,267)</b>
Library	(129)	(6)	-	-	<b>(135)</b>
	<b>(593,561)</b>	<b>(62,653)</b>	<b>8,749</b>	<b>17</b>	<b>(647,448)</b>

  

	<b>Consolidated</b>					
	<b>Change in the period</b>					
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	<b>Sale of investment (b)</b>	<b>06/30/15</b>
Properties	(2,122)	(94)	-	375	-	<b>(1,841)</b>
Leasehold improvements	(267,628)	(21,422)	261	(376)	66	<b>(289,099)</b>
Machinery and equipment	(234,275)	(28,698)	8,554	327	635	<b>(253,457)</b>
Furniture and fixtures	(25,321)	(3,203)	598	(23)	44	<b>(27,905)</b>
Facilities	(22,951)	(3,495)	41	(17)	52	<b>(26,370)</b>
IT equipment	(62,313)	(8,686)	1363	(269)	33	<b>(69,872)</b>
Vehicles	(4,603)	(137)	326	-	-	<b>(4,414)</b>
Library	(138)	(6)	-	-	-	<b>(144)</b>
	<b>(619,351)</b>	<b>(65,741)</b>	<b>11,143</b>	<b>17</b>	<b>830</b>	<b>(673,102)</b>

(a) Depreciation related to expenses made by the Company classified under Construction in progress for the construction, installation and development period, which are transferred to a specific account of property and equipment or intangible assets when available for use.

(b) Changes in the period of discontinued operations, as mentioned in Note 13.

A portion of additions to accumulated depreciation, as shown in changes in property and equipment, was recorded under "General and administrative expenses" account, and another portion under "Cost of products sold and/or services rendered" account.

Over the period, the Company has neither identified indicators of impairment of assets, nor capitalized interest.

**Notes to quarterly information****16. Intangible assets**

	Average amortization rate % p.a.	Company			
		06/30/15		12/31/14	
		Cost	Accumulated amortization	Net	Net
Acquisition of interest - Goodwill		<b>2,102,999</b>	<b>(142,396)</b>	<b>1,960,603</b>	1,961,854
Other intangible assets					
IT system	20	243,791	(149,419)	94,372	100,700
Commercial area use right	20	5,538	(1,093)	4,445	704
Other intangible assets	20	12,628	(5,059)	7,569	8,146
System implementation project	20	12,293	(12,293)	-	-
Project development	33	10,259	(10,215)	44	93
Brands	3.3	236,037	(35,592)	200,445	204,161
Exclusive agreement with customers - Unimagem	10	9,403	(6,112)	3,291	3,926
Relationship with hospitals	5	35,748	(8,044)	27,704	28,606
		<b>565,697</b>	<b>(227,827)</b>	<b>337,870</b>	346,336
		<b>2,668,696</b>	<b>(370,223)</b>	<b>2,298,473</b>	2,308,190
		Consolidated			
		06/30/15		12/31/14	
	Average amortization rate % p.a.	Cost	Accumulated amortization	Net	Net
Acquisition of interest - Goodwill		<b>2,233,505</b>	<b>(248,574)</b>	<b>1,984,931</b>	1,986,182
Other intangible assets					
IT system	20	247,864	(152,982)	94,882	101,389
Commercial area use right	20	5,539	(1,093)	4,446	704
Other intangible assets	20	13,978	(5,216)	8,762	9,473
System implementation project	20	12,293	(12,293)	-	-
Project development	33	10,267	(10,217)	50	98
Brands	3.3	251,161	(37,846)	213,315	218,577
Exclusive agreement with customers - Unimagem	10	9,403	(6,112)	3,291	3,926
Relationship with hospitals	5	39,894	(9,832)	30,062	29,747
		<b>590,399</b>	<b>(235,591)</b>	<b>354,808</b>	363,914
		<b>2,823,904</b>	<b>(484,165)</b>	<b>2,339,739</b>	2,350,096

**Notes to quarterly information**Changes in cost

	<b>Company</b>				<b>06/30/15</b>
	<b>Change in the period</b>				
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	
Acquisition of interest - Goodwill	2,104,250	-	(1,251)	-	<b>2,102,999</b>
Other intangible assets					
IT system	234,917	15,136	(2,058)	(4,204)	<b>243,791</b>
Commercial area use right	1,433	4,335	(230)	-	<b>5,538</b>
Other intangible assets	12,628	-	-	-	<b>12,628</b>
System implementation project	12,293	-	-	-	<b>12,293</b>
Project development	10,259	-	-	-	<b>10,259</b>
Brands	236,037	-	-	-	<b>236,037</b>
Exclusive agreement with customers					
- Unimagem	9,403	-	-	-	<b>9,403</b>
Relationship with hospitals	35,748	-	-	-	<b>35,748</b>
	<b>552,718</b>	<b>19,471</b>	<b>(2,288)</b>	<b>(4,204)</b>	<b>565,697</b>
	<b>2,656,968</b>	<b>19,471</b>	<b>(3,539)</b>	<b>(4,204)</b>	<b>2,668,696</b>
	<b>Consolidated</b>				<b>06/30/15</b>
	<b>Change in the period</b>				
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	
Acquisition of interest - Goodwill	2,234,756	-	(1,251)	-	<b>2,233,505</b>
Other intangible assets					
IT system	238,986	15,139	(2,057)	(4,204)	<b>247,864</b>
Commercial area use right	1,433	4,336	(230)	-	<b>5,539</b>
Other intangible assets	13,978	-	-	-	<b>13,978</b>
System implementation project	12,293	-	-	-	<b>12,293</b>
Project development	10,267	-	-	-	<b>10,267</b>
Brands	251,161	-	-	-	<b>251,161</b>
Exclusive agreement with customers					
- Unimagem	9,403	-	-	-	<b>9,403</b>
Relationship with hospitals	39,894	-	-	-	<b>39,894</b>
	<b>577,415</b>	<b>19,475</b>	<b>(2,287)</b>	<b>(4,204)</b>	<b>590,399</b>
	<b>2,812,171</b>	<b>19,475</b>	<b>(3,538)</b>	<b>(4,204)</b>	<b>2,823,904</b>

- (a) Expenses made by the Company classified under Construction in progress for the construction, installation and development period, which are transferred to a specific account of property and equipment or intangible assets when available for use.

## Notes to quarterly information

### Changes in accumulated amortization

	<b>Company</b>					
	<b>Change in the period</b>					
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	<b>06/30/15</b>	
Acquisition of interest - Goodwill	(142,396)	-	-	-	(142,396)	
Other intangible assets						
IT system	(134,217)	(16,621)	1,436	(17)	(149,419)	
Commercial area use right	(729)	(364)	-	-	(1,093)	
Other intangible assets	(4,482)	(577)	-	-	(5,059)	
System implementation project	(12,293)	-	-	-	(12,293)	
Project development	(10,166)	(49)	-	-	(10,215)	
Brands	(31,876)	(3,901)	-	185	(35,592)	
Exclusive agreement with customers - Unimagem	(5,477)	(465)	-	(170)	(6,112)	
Relationship with hospitals	(7,142)	(887)	-	(15)	(8,044)	
	(206,382)	(22,864)	1,436	(17)	(227,827)	
	(348,778)	(22,864)	1,436	(17)	(370,223)	
	<b>Consolidated</b>					
	<b>Change in the period</b>					
	<b>12/31/14</b>	<b>Additions</b>	<b>Write-offs</b>	<b>Transfers (a)</b>	<b>Sale of investment (b)</b>	<b>06/30/15</b>
Acquisition of interest - Goodwill	(248,574)	-	-	-	-	(248,574)
Other intangible assets						
IT system	(137,597)	(16,837)	1,434	(12)	30	(152,982)
Commercial area use right	(729)	(364)	-	-	-	(1,093)
Other intangible assets	(4,505)	(711)	-	-	-	(5,216)
System implementation project	(12,293)	-	-	-	-	(12,293)
Project development	(10,169)	(48)	-	-	-	(10,217)
Brands	(32,584)	(4,151)	-	(1,111)	-	(37,846)
Exclusive agreement with customers - Unimagem	(5,477)	(465)	-	(170)	-	(6,112)
Relationship with hospitals	(10,147)	(961)	-	1,276	-	(9,832)
	(213,501)	(23,537)	1,434	(17)	30	(235,591)
	(462,075)	(23,537)	1,434	(17)	30	(484,165)

(a) Amortization related to expenses made by the Company classified under Construction in progress for the construction, installation and development period, which are transferred to a specific account of property and equipment or intangible assets when available for use.

(b) Changes in the period of discontinued operations, as mentioned in Note 13.

A portion of additions to accumulated amortization, as shown in changes in property and equipment, was recorded under "General and administrative expenses" account, and another portion under "Costs of sales and/or services" account.

Over the period, the Company has neither identified indicators of impairment of assets, nor capitalized interest.

**Notes to quarterly information****17. Loans and financing**

Type	Average charges	Final maturity	Company		Consolidated	
			06/30/15	12/31/14	06/30/15	12/31/14
<b>Local currency</b>						
Banco do Brasil	108.0% of CDI	06/10/2018	51,853	71,650	51,853	71,650
Banco Santander	90.13% of CDI 6% p.a. to 9.5% p.a.	03/14/2016	36,077	-	36,077	-
BNDES - FINAME PSI (ii) (v) Finance lease - Various banks - Note 27 (v)	CDI + 2.03% p.a.	12/15/2024 10/14/2016	10,719 1,506	7,083 3,797	10,719 1,506	7,083 3,797
			<b>100,155</b>	82,530	<b>100,155</b>	82,530
<b>Foreign currency</b>						
Equipment financing (i), (ii) and (v) Finance lease - Various banks - Note 27 (ii) Banco Credit Agricole (iii) (iv)	6.52% p.a. 2.97% p.a. 1.32% p.a.	12/01/2016 03/23/2016 07/15/2015	1,065 444 -	1,331 2,062 -	1,065 444 94,153	1,331 2,062 80,077
			<b>1,509</b>	3,393	<b>95,662</b>	83,470
			<b>101,664</b>	85,923	<b>195,817</b>	166,000
Current liabilities			<b>(56,085)</b>	(34,634)	<b>(150,238)</b>	(114,711)
Noncurrent liabilities			<b>45,579</b>	51,289	<b>45,579</b>	51,289

**Guarantors**

- (i) DASA Real Estate Empreendimentos Imobiliários Ltda.
- (ii) Promissory Note of 125% of contractual amount in the Company's name.
- (iii) Diagnósticos da América S.A.
- (iv) Bank guarantee and marketable securities in guarantee are government securities and corporate bonds acquired by subsidiary DASA Finance Corporation.
- (vi) Asset financed.

Bank loans and financing agreements do not have covenants.

Bank loans and financing classified in noncurrent liabilities, according to contractual maturities, will be amortized as follows:

	Company and consolidated
From July 2016	9,472
2017	18,430
2018	9,973
From 2019 to 2024	7,704
	<b>45,579</b>

The Company granted a collateral of R\$72,911 to subsidiary DASA Finance Corporation jointly with Banco do Brasil.

**Notes to quarterly information****18. Debentures (company and consolidated)**

	<u>06/30/15</u>	<u>12/31/14</u>
Non-convertible debentures	1,208,334	1,041,667
Conventional interest	36,060	24,589
	<u>1,244,394</u>	<u>1,066,256</u>
Transaction cost	(4,993)	(3,999)
	<u>1,239,401</u>	<u>1,062,257</u>
Current	(329,989)	(318,932)
Noncurrent	<u>909,412</u>	<u>743,325</u>

Deadline for amortization of principal of second-, third-, fourth- and five-issues of debentures is as follows:

10/25/2015	62,500
04/29/2016	233,334
10/25/2016	62,500
10/17/2017	225,000
03/10/2018	249,820
10/17/2018	225,000
03/10/2020	150,180
	<u>1,208,334</u>

**2<sup>nd</sup> Issue**

In the meeting held on March 16, 2011, the Board of Directors of the Company approved a fund raising by conducting the 2<sup>nd</sup> issue of simple debentures non-convertible into shares of the Company, for public distribution in the total amount of up to R\$810,000, on a firm guarantee and better efforts of placement basis, under the terms of CVM Ruling No. 476 of January 16, 2009, as amended.

On May 16, 2011, the Company communicated to its shareholders and the market in general that on May 11, 2011 it had closed the public offer for distribution of simple debentures not convertible into shares, of the unsecured type of DASA second issue, in one single series, with restricted placement efforts. Seventy thousand (70,000) debentures were subscribed for a 5-year term from the date of issue, in the total amount of R\$700,000. The debenture remuneration is equivalent to 100% of the accumulated variation of the Interbank Deposit (DI) daily average rates, "over extragroup", expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by the Clearing House for the Custody and Financial Settlement of Securities (CETIP), plus an exponential surcharge of 1.40%. As the issue date was April 29, 2011, the face value of each debenture will be paid in 3 consecutive annual installments, as from the 36<sup>th</sup> month from the issue date. Payment of remuneration interest is semiannual, occurring on the 1<sup>st</sup> day of April and October, and the debit in the Company account shall occur one day prior to due date.



## Notes to quarterly information

### 3<sup>rd</sup> Issue

On October 15, 2012, the Board of Directors of the Company approved the third issue by the Company, of up to 25,000 debentures non-convertible into shares of the unsecured type, in a single series, in the total amount of up to R\$250,000, for placement through a public offer with restricted efforts, pursuant to CVM Ruling No. 476 of January 16, 2009, as amended.

On November 1, 2012, the Company communicated to its shareholders and the market in general that on October 31, 2012 it had closed the public offer for distribution of simple debentures not convertible into shares, of the unsecured type of DASA third issue, in one single series, with restricted placement efforts. Twenty-five thousand (25,000) debentures were subscribed for a 4-year term from the date of issue, in the total amount of R\$250,000. The debentures are not subject to monetary adjustment, and the debit balance of each debenture face value will incur an interest equivalent to 100% of the accumulated variation of the Interbank Deposit (DI) daily average rates, "over extragroup", expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by CETIP, plus a surcharge of 0.80% per annum, calculated based on 252 business days, exponentially and cumulatively, on a pro rata temporis basis, per business day elapsed from the Date of Issue or the payment date of the immediately prior remuneration, as the case may be, until the effective payment date.

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 25, 2013 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

The face value of each Debenture will be repaid in 4 annual and successive installments, in the following order:

- I. Three installments, each in the amount corresponding to 25% of the face value of each Debenture, due on October 25, 2013, October 25, 2014 and October 25, 2015; and
- II. One installment in the amount corresponding to the outstanding balance of the face value of each Debenture, due on October 25, 2016.

The financial settlement of the offer occurred on October 31, 2012 in the amount of R\$250,304, and the net proceeds of the offer were used towards (i) the early redemption of all commercial promissory notes of the third issue of the Company; and (ii) the balance to reinforce the working capital of the Company.

### 4<sup>th</sup> Issue

On September 13, 2013, the Company's Board of Directors approved the fourth issue of debentures by the Company, in a single series of up to 45,000 unsecured debentures not convertible into shares totaling up to R\$450,000 for placement through public offering with restrict placement efforts under the terms of CVM Ruling No. 476 of January 16, 2009, as amended.

## Notes to quarterly information

On October 18, 2013, the Company communicated its shareholders and the general market that the public offering with restricted placement efforts of simple, unsecured debentures not convertible into shares, in a single series, of the 4<sup>th</sup> issue was concluded on October 17, 2013. Forty-five thousand (45,000) debentures, effective for 5 years from issue date, amounting to R\$450,000 were subscribed. These debentures will not be subject to monetary restatement and, over the debt balance of the nominal value of each debenture, conventional interest will be levied, corresponding to 100% of accumulated daily average interbank deposits (DI) rate, "over extragroup", expressed in percentage per year, on a 252 business days basis and disclosed by CETIP plus a surtax of 1.15% per annum, on a 252 business days basis, computed on an exponential and cumulative manner, pro rata temporis, per business days elapsed since payment date or the date when the prior remuneration is paid, as the case may be, until the effective payment.

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 15, 2014 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

Principal amount will be amortized in two annual installments, in the 48<sup>th</sup> and 60<sup>th</sup> month, as from the debentures issue date.

Financial settlement of this offering occurred on October 16, 2013, amounting to R\$450,000 and the net funds from the offering were used to reinforce the working capital and refinancing of debts.

### 5<sup>th</sup> Issue

On February 9, 2015, the Company Board of Directors approved the fifth issue by the Company of up to two series of up to, at least, 40,000 debentures and no more than 50,000 debentures not convertible into unsecured shares at par value of R\$10, amounting to at least R\$400,000 and no more than R\$500,000, on the issue date, i.e. March 10, 2015, for placement through public offering with restricted placement efforts, pursuant to CVM Ruling No. 476, of January 16, 2009, as amended.

On March 26, 2015 the public offering with restricted efforts for placement of simple debentures not convertible into unsecured shares in two series of the fifth issue of the Company was completed. Forty thousand (40,000) debentures were subscribed.

The three-year first series as from the date of issue, amounting to R\$249,820. The Debentures will not be subject to monetary restatement, the debt balance of the par value of each Debenture shall bear conventional interest of 100% of the accumulated variation of the average daily rates of DI – one-day interbank deposits "over extragroup", expressed as a percentage per annum, based on 252 business days, calculated and announced by CETIP, plus the additional rate of 1.05% per annum, based on 252 business days, calculated on an exponential and cumulative pro rata temporis basis by business days elapsed, as from the date of payment, or the date of payment of the immediately previous compensation, as the case may be, until the date of the actual payment. The principal amount shall be amortized in two annual installments, in the 24<sup>th</sup> and 36<sup>th</sup> months, as from the date of issue of debentures.

The 5-year second series as from the date of issue, amounting to R\$150,180. The Debentures shall not be subject to monetary restatement and the debt balance of the par value of each Debenture shall bear conventional interest of 100% of the accumulated variation of average daily rates of DI – one-day interbank deposits "over extragroup," expressed as a percentage per annum, based on 252 business days, calculated and announced by CETIP, plus the additional rate of 1.20% per annum, based on 252 business days, calculated on an exponential and cumulative pro rata temporis basis by business days elapsed, as from the date of payment or the date of payment of the immediately previous compensation, as the case may be, until the date of the actual payment. The principal amount shall be amortized in two annual installments, in the 48<sup>th</sup> and 60<sup>th</sup> month, as from the date of issue of debentures.

## Notes to quarterly information

The compensation shall be paid semi-annually as from the date of issue, the first payment on September 10, 2015 and the last one on the date of maturity, notwithstanding the payments in connection with the early redemption of the Debentures, early amortization of Debentures and/or early maturity of the obligations arising from Debentures.

The offering was financially settled between March 20 and 23, 2015, amounting to R\$400,000 and net funds from issue by the Company shall be fully used to refinance the Company's short-term debts, including the amortization of the principal amount and the payment of interest of second and third issue of the Company, and the balance, if any, shall be used to increase working capital.

The debentures have clauses setting the maximum indebtedness and leverage levels, based on consolidated quarterly information.

At June 30, 2015, the Company was compliant with these covenants, as follows:

Indicator	Covenant (a)	Covenant at 06/30/15	Covenant at 12/31/14
EBITDA - past 12 months (b)		341,964	416,056
Financial income (expense) - past 12 months		96,425	100,971
Net debt		811,319	788,032
1. Net debt / EBITDA - maximum index			
2 <sup>nd</sup> Issue	2.50	2.37	1.89
3 <sup>rd</sup> Issue	3.00	2.37	1.89
4 <sup>th</sup> Issue	3.00	2.37	1.89
5 <sup>th</sup> Issue	3.00	2.37	1.89
2- EBITDA / Financial income (expense) - minimum index			
2 <sup>nd</sup> Issue	2.00	3.54	4.12
3 <sup>rd</sup> Issue	2.00	3.54	4.12
4 <sup>th</sup> Issue	2.00	3.54	4.12
5 <sup>th</sup> Issue	2.00	3.54	4.12

(a) The Company will be deemed non-compliant with this covenant if it exceeds such ratios for two consecutive quarters.

(b) The information and EBITDA above is not part of the scope of work in the independent auditor's review.

## 19. Accounts payable for acquisitions of subsidiaries

Accounts payable for acquisition of subsidiaries relate to the amounts due to their former owners upon the acquisition of shares or units of interest representing the paid-in capital of these companies. Debts are restated in accordance with contractual clauses:

	Restatement	Maturity	Company		Consolidated	
			06/30/15	12/31/14	06/30/15	12/31/14
Not guaranteed by marketable securities	IPCA-IGPM-Selic	05/2016	5,517	8,493	5,517	8,493
Guaranteed by Marketable securities	(a)	11/2016 and 04/2017	7,957	15,427	18,596	25,555
			<b>13,474</b>	23,920	<b>24,113</b>	34,048
Current			<b>(1,071)</b>	(3,783)	<b>(1,071)</b>	(3,783)
Noncurrent			<b>12,403</b>	20,137	<b>23,042</b>	30,265

(a) Restated at the average rate of 106.13% of CDI (105.39% of CDI at December 31, 2014) for fixed-income funds, and 103.42% of CDI (100.01% of CDI at December 31, 2014) for CDB/repurchase agreements, which are managed by financial entities, as shown in Note 9.

## Notes to quarterly information

The portions classified in noncurrent liabilities have the following payment schedule:

Year of maturity	Company	Consolidated
From July 2016	12,287	18,556
From 2017 to 2020	116	4,486
Total	12,403	23,042

## 20. Provisions for tax, social security, civil and labor contingencies

	Company			
	06/30/15		12/31/14	
	Provision	Judicial deposit	Provision	Judicial deposit
ICMS on import (a)	17,160	1,709	5,692	1,653
Labor and civil contingencies (b)	15,672	12,089	17,586	12,936
Tax contingencies (c)	36,260	50,736	35,776	46,678
	69,092	64,534	59,054	61,267
	Consolidated			
	06/30/15		12/31/14	
	Provision	Judicial deposit	Provision	Judicial deposit
ICMS on import (a)	17,160	1,709	5,692	1,653
Labor and civil contingencies (b)	15,762	13,168	17,676	13,948
Tax contingencies (c)	36,992	51,391	36,508	47,333
	69,914	66,268	59,876	62,934

### (a) ICMS on import

Following the opinion of its legal advisors, the Company has not paid ICMS on the import of inputs and equipment for use in the rendering of its services since February 2000, as there are ongoing discussions as to whether the Company should pay ICMS on these transactions.

As regards the ICMS payables over input and equipment imported up to the publication of Constitutional amendment No. 33 of December 11, 2001, the external legal advisors understand that the likelihood of loss is remote; but as to ICMS payables generated between the Constitutional Amendment No. 33 date and the issuance of the supplementary Law No. 114 of December 16, 2002, the likelihood of loss was rated as possible. For import of equipment under lease agreement, the likelihood of loss was also deemed possible, except for a tax delinquency notice under administrative phase of judgment, whose likelihood of loss was changed to probable by external legal advisors who defend the cause. On account of this risk reassessment, management was required to set up an additional provision in this account corresponding to R\$12,031, out of which R\$8,812 is recorded under "Financial expenses" and R\$3,219 under "Construction in Progress" since it refers to equipment acquisition. Finally, after enactment of the Supplementary Law No. 114 of December 16, 2002, the external legal advisors understand that the likelihood of loss is probable, for which the Company has set up a provision amounting to R\$17,160 (R\$5,692 at December 31, 2014), with judicial deposits amounting to R\$1,709, both restated by the Central Bank benchmark rate (SELIC).

### (b) Provisions for tax, civil and labor contingencies

At June, 2015, the Company was a party to 1,693 labor claims (1,628 at December 31, 2014) and to 1,193 legal and administrative proceedings of a civil nature (1,233 at December 31, 2014). The provisions of R\$15,672 (R\$17,586 at December 31, 2014) in the Company and R\$15,762 (R\$17,676 at December 31, 2014) in consolidated are based on the historical percentage of loss of proceedings whose likelihood of an unfavorable outcome had been rated as probable, possible and remote. At June 30, 2015, the Company presented the consolidated amount of R\$90,664 (R\$89,304 at December 31, 2014) related to proceedings classified by its legal advisors as possible loss, of which R\$23,172 refers to civil proceedings and R\$67,942 to labor claims. The Company does not set up provisions for amounts liable to estimated risks in proceedings that are under the responsibility of the sellers of acquires, which correspond to (i) R\$11,857 referring to labor claims, and (ii) R\$4,228 referring to legal and administrative proceedings of a civil nature that are guaranteed by marketable securities, as mentioned in Note 9 (a).

## Notes to quarterly information

The Company is also a party to a lawsuit for indemnification for loss of profits and pain and suffering due to supposed competition-related infraction by the Company together with a health insurance company. An opposition was filed against the case amount against which claimants filed a reply, as such, an expert accounting and engineering examination was ordered. On December 7, 2007, the amount attributed to the case by claimant was R\$61,815. The likelihood of loss in this lawsuit was deemed as possible, and it is not yet possible to estimate the amount the Company is likely to lose. An expert accounting examination conducted by the court expert concluded that the claimed loss of profit should amount to R\$4,500, applicable to the health plan insurance company and not to the Company.

As regards labor claims classified as possible loss, it should be mentioned the Public Civil Action at the Rio de Janeiro Labor Court, to which the Company and Laboratórios Médicos Dr. Sérgio Franco Ltda. (an entity merged by the Company on July 1, 2014) are a party. In general, the Public Civil Action questions the legality of the arrangements with health companies specialized in imaging diagnostic support services, which required hiring physicians bound to said healthcare companies under the Consolidation of Labor Laws (CLT) and a collective indemnification for pain and suffering of approximately R\$20,000 on September 10, 2012. On June 26, 2014, the Company issued a Material News Release disclosing that a decision was handed down by the lower court favoring the Company. On February 24, 2015, the Regional Labor Court partially granted the appeal filed by the Public Prosecution Service and sentenced the Company to formally hire the intervening doctors, which represents nearly 22 professionals, besides reducing the collective pain and suffering to R\$ 500. The Company and the Public Prosecutor's Office filed motions for clarification against the decision. The motions for clarification of the Public Prosecutor's Office were denied and those of the Company were accepted, however, without granting amending effect to the final decision. A possible review of the appeal is expected to be filed by the Public Prosecutor's Office. Due to the strategy adopted by the Company, legal advisors and management understand that the likelihood of loss is probable for the collective pain and suffering damages, in the amount of R\$500, and for the registration of approximately 22 professionals.

### (c) Provisions for tax contingencies

The provisions for tax contingencies in the amount of R\$36,260 (R\$35,776 at December 31, 2014) in Company and R\$36,992 (R\$36,508 at December 31, 2014) in consolidated relate to: (i) questionings for increases in rates; (ii) calculation base; and (iii) unconstitutionality of collection. Such questionings refer basically to PIS, COFINS, INSS and FGTS contributions. At June 30, 2015 the Company also had the consolidated amount of R\$205,422 (R\$282,275 at December 31, 2014) related to proceedings classified by its legal advisors as possible loss, for which there were no provisions, according to the accounting rule applicable for those circumstances, and substantially R\$24,250 was related to ICMS proceedings over import of leased equipment and direct import of inputs and equipment performed between the EC33 (enacted in December 2001) and Supplementary Law No. 114 (enacted in December 2002); R\$62,002 referring to ISS proceedings, which basically challenge the local were the clinical analysis services were rendered; and R\$119,170 related to other PIS, COFINS, IRPJ and CSSL tax proceedings. The Company does not set up provisions for amounts liable to estimated risks in proceedings that are under the responsibility of the sellers of acquires, which correspond to R\$7,130 basically referring to ICMS, INSS, IRPJ and CSSL, which are guaranteed by marketable securities, as mentioned in Note 9 (a).

### Changes in provisions for contingencies

	Company				
	12/31/14	Change in the period			06/30/15
	Closing balance	Addition to provision	Use	Update	Closing balance
ICMS on import	5,692	3,219	(563)	8,812	17,160
Provision for labor and civil contingencies	17,586	7,115	(9,478)	449	15,672
Provision for tax contingencies	35,776	-	(638)	1,122	36,260
	59,054	10,334	(10,679)	10,383	69,092
	Consolidated				
	12/31/14	Change in the period			06/30/15
	Closing balance	Addition to provision	Use	Update	Closing balance
ICMS on import	5,692	3,219	(563)	8,812	17,160
Provision for labor and civil contingencies	17,676	7,115	(9,478)	449	15,762
Provision for tax contingencies	36,508	-	(638)	1,122	36,992
	59,876	10,334	(10,679)	10,383	69,914

## Notes to quarterly information

### 21. Equity

#### a) Share-based payment

##### *Changes in the period of stock options granted in June 2012*

In June 2012, the Executive Board and the beneficiaries of the plan entered into stock option grant agreements. The number of shares initially granted was 259,959 common registered shares, currently 140,425 (192,947 at December 31, 2014) common registered shares granted considering the contracts canceled up to June 30, 2015, with Vesting Period until June 2015.

	<b>Common registered shares</b>	<b>R\$</b>	<b>Share value</b>
Balance at December 31, 2014	162,083	1,769	10.91
Cancellations	(10,807)	(117)	
Settlements	(39,870)	(561)	
Additions	29,019	334	
Balance at June 30, 2015	140,425	1,425	10.15

The details of the Stock Option Plan are set out in Note 22 (b) to the financial statements for the year ended December 31, 2014.

#### b) Treasury shares

<b>Operation description</b>	<b>Number of shares</b>	<b>Amount</b>	<b>Average price per share</b>
Balance at June 30, 2015 and December 31, 2014	1,052,459	16,905	16.06

#### c) Earnings per share

##### *Basic*

Basic earnings per share is calculated by dividing the net income attributable to the Company's shareholders by the weighted average number of common shares issued over the period excluding common shares purchased by the Company and held as treasury shares.

	<b>01/01/2015 to 06/30/2015</b>	<b>01/01/2014 to 06/30/2014</b>
Income attributable to the Company's controlling shareholders	<b>10,018</b>	60,330
Weighted average number of common shares issued	<b>311,803</b>	311,803
Weighted average of treasury shares	<b>(1,052)</b>	(1,052)
Weighted average number of outstanding common shares	<b>310,751</b>	310,751
Basic earnings per share - R\$	<b>0.03224</b>	0.19414

## Notes to quarterly information

### *Diluted*

Diluted earnings per share is computed by adjusting the weighted average number of outstanding shares assuming the conversion of all potential common shares that would cause the dilution. The Company has only one category of dilutive potential common shares: options of the stock option plan disclosed in item (a) of this note.

	<b>01/01/2015 to 06/30/2015</b>	<b>01/01/2014 to 06/30/2014</b>
Income attributable to the Company's controlling shareholders	<b>10,018</b>	60,330
Weighted average number of outstanding common shares	<b>310,751</b>	310,751
Adjustments for stock option plan	<b>140</b>	212
Weighted average number of common shares for diluted earnings per share	<b>310,891</b>	310,963
Diluted earnings per share - R\$	<b>0.03222</b>	0.19401

### d) Capital

At the trial session held on July 16, 2014 by the Brazil's Administrative Council for Economic Defense ("CADE"), the acquisition of the Company's common shares by Cromossomo Participações II S/A was approved. Consequently, Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (shareholders who indirectly owns the total capital of Cromossomo), now control, both directly and indirectly, more than 70% of the Company's capital, as described in the Merger Review Process No. 08700.002372/2014-07. The referred to approval granted by CADE was conditioned on compliance with the Merger Control Agreement ("MCA"), a mechanism of the current competition defense law (Law No. 12529/11) that is equivalent to the former Performance Commitment Agreement, applied under Law No. 8884/94.

Under the MCA, Cromossomo's shareholders are compelled to formally follow the obligations that have already been provided for in the Performance Commitment Agreement entered into between the Company and CADE, in the records of the Merger Review Process No. 08012.010038/2010-4, which analyzed the association among the Company, MD1 Diagnósticos S.A. and other companies, as notified in the Material News Release disclosed by the Company on December 4, 2013.

## 22. Income and social contribution taxes

The Company records monthly provisions for income and social contribution taxes on an accrual basis.

Taxes are calculated by the taxable profit regime, whereby taxes are computed based on the company's accounting records, except for subsidiaries Multi-Imagem Petrópolis and Dasa Property, on which the regime whereby profit is computed as a percentage of the company's gross revenue was adopted.

**Notes to quarterly information**

Reconciliation of the expense calculated by applying combined tax rates for income and social contribution tax expenses charged to P&L is as follows:

	<b>Company</b>		<b>Consolidated</b>	
	<b>06/30/15</b>	<b>06/30/14</b>	<b>06/30/15</b>	<b>06/30/14</b>
Income before income and social contribution taxes	<b>22,459</b>	67,097	<b>21,666</b>	88,625
	<b>34%</b>	34%	<b>34%</b>	34%
Income and social contribution taxes: at combined tax rate	<b>(7,636)</b>	(22,813)	<b>(7,366)</b>	(30,133)
<b>Permanent exclusions (additions)</b>				
Equity pickup	<b>107</b>	19,359	-	-
Interest in paid-in capital	<b>(74)</b>	(2,655)	-	-
Nondeductible expenses	<b>(818)</b>	(658)	<b>(829)</b>	(676)
<b>Other adjustments</b>				
Income of subsidiary abroad	-	-	<b>1,213</b>	1,036
Taxable profit computed as a percentage of gross sales (Deemed profit taxation)	-	-	<b>123</b>	509
Goodwill on downstream merger	-	-	-	764
Adjustment - Equity pick-up - Discontinued operations	-	-	<b>554</b>	-
Supplement deferred tax on goodwill	<b>(4,020)</b>	-	<b>(4,020)</b>	-
Other	-	-	<b>(1,153)</b>	408
	<b>(12,441)</b>	(6,767)	<b>(11,478)</b>	(28,092)
Current income and social contribution Taxes	-	-	<b>(1,022)</b>	(21,348)
Deferred taxes	<b>(12,441)</b>	(6,767)	<b>(10,456)</b>	(6,744)
Total	<b>(12,441)</b>	(6,767)	<b>(11,478)</b>	(28,092)
Effective rate	<b>-55%</b>	-10%	<b>-53%</b>	-32%

The 34% combined tax rate used for 2015 and 2014 calculations applies to taxable profit of legal entities in Brazil as required by the tax laws of this jurisdiction.

Deferred taxes on tax losses and temporary provisions

Deferred income and social contribution taxes are recorded to reflect the future tax effects attributable to the temporary differences between the tax base of assets and liabilities and their respective book value.

In accordance with CPC 32, based on the expected generation of future taxable profit backed by a technical study approved by management, the Company recognizes tax credits and debits on deductible temporary differences and accumulated income and social contribution tax losses, which are not subject to limitation and may be used to offset up to 30% of annual taxable profit. The book value for deferred tax assets and liabilities is reviewed on a quarterly and projections are reviewed annually.



**Notes to quarterly information**

Breakdown of deferred income and social contribution tax assets and liabilities are as follows:

	<b>Balance sheet</b>		<b>Income (loss)</b>
	<b>Company</b>		<b>Company</b>
	<b>06/30/15</b>	<b>12/31/14</b>	<b>06/30/15</b>
Income tax losses and negative basis for social contribution	<b>202,403</b>	198,309	4,094
Allowance for doubtful accounts and disallowances	<b>20,975</b>	15,045	5,931
Provision for specialized medical services	<b>13,520</b>	11,402	2,119
Sundry provisions	<b>11,904</b>	1,997	9,907
Provision (-) Obsolete items	<b>769</b>	317	451
Provision for contingencies	<b>19,468</b>	15,892	3,576
Other	<b>1,354</b>	3,045	(1,691)
Goodwill amortization	<b>(319,695)</b>	(281,385)	(38,310)
Intangibles identified in acquisitions	<b>(78,814)</b>	(80,616)	1,801
Review of property and equipment useful lives	<b>(8,791)</b>	(8,559)	(232)
Outros	<b>(7,326)</b>	(7,239)	(87)
<b>Deferred income and social contribution taxes - Assets</b>			
<b>/ (Liabilities)</b>	<b>(144,234)</b>	(131,792)	-
<b>Revenue (expenses) from income and social contribution - deferred</b>	-	-	(12,441)
<b>Reflected in the balance sheet as follows</b>			
Deferred tax assets	-	-	
Deferred tax liabilities	<b>(144,234)</b>	(131,792)	
<b>Deferred income and social contribution taxes - Assets</b>			
<b>/(Liabilities)</b>	<b>(144,234)</b>	(131,792)	
<b>Reconciliation of tax assets (liabilities) - deferred</b>	<b>12/31/14</b>		
Opening Balance	<b>(131,792)</b>		
Income / (expenses) from taxes recognized in income (loss)	<b>(12,441)</b>		
<b>Balance at June 30, 2015</b>	<b>(144,234)</b>		

**Notes to quarterly information**

	Balance sheet Consolidated		Income (loss) Consolidated
	06/30/15	12/31/14	06/30/15
Income tax losses and negative basis for social contribution	246,770	240,628	6,142
Allowance for doubtful accounts and disallowances	28,788	20,539	8,249
Goodwill amortization	5,614	7,936	(2,322)
Provision for specialized medical services	13,623	11,512	2,111
Sundry provisions	11,973	2,094	9,879
Provision (-)Obsolete items	914	386	528
AVP - Accounts receivable long term	-	301	(301)
Provision for contingencies	19,722	16,146	3,576
Other	1,354	3,045	(1,691)
Goodwill amortization	(320,326)	(282,016)	(38,310)
Intangibles identified in acquisitions	(83,993)	(85,904)	1,911
Review of useful life of property and equipment	(9,388)	(9,250)	(138)
Other	(7,326)	(7,240)	(86)
<b>Deferred income and social contribution taxes - Assets/ (Liabilities)</b>	<b>(92,278)</b>	<b>(81,822)</b>	
<b>Revenue (expenses) from income and social contribution taxes - deferred</b>			<b>(10,456)</b>
<b>Reflected in the balance sheet as follows:</b>			
Deferred tax assets	55,777	53,028	
Deferred tax liabilities	(148,055)	(134,850)	
<b>Deferred income and social contribution taxes - Assets/ (Liabilities)</b>	<b>(92,278)</b>	<b>(81,822)</b>	
<b>Reconciliation of deferred tax assets (liabilities)</b>	<b>12/31/14</b>		
Opening Balance	(81,822)		
Income / (expenses) from taxes recognized in income (loss)	(10,456)		
Other			
<b>Balance at June 30, 2015</b>	<b>(92,278)</b>		

Company management considers that the deferred income and social contribution tax asset balances from temporary differences will be realized to the proportion of the contingencies and realization of events triggering such provisions for losses.

During the six-month period, the Company has not identified indications that deferred taxes will not be recovered.

**23. Cost of services rendered**

	Company		Consolidated	
	06/30/15	06/30/14	06/30/15	06/30/14
Personnel	250,802	187,821	283,148	262,785
Material	234,143	162,742	258,238	243,667
Services and utilities	359,118	271,446	374,145	346,478
Depreciation and amortization	58,063	40,963	59,914	54,335
General expenses	14,990	12,933	17,152	16,709
	<b>917,116</b>	<b>675,905</b>	<b>992,597</b>	<b>923,974</b>

## Notes to quarterly information

### 24. General and administrative expenses by nature

	Company		Consolidated	
	06/30/15	06/30/14	06/30/15	06/30/14
Personnel expenses	121,626	85,557	133,059	117,875
Provision for profit sharing and bonus	25,890	19,800	25,890	19,800
Services and utilities	52,139	41,059	58,313	59,894
Advertising and publicity	6,322	4,170	6,588	4,799
Freight	24,232	17,813	26,579	21,132
Depreciation and amortization	27,455	30,728	28,503	31,559
Taxes and charges	7,622	622	9,713	1,380
Sundry provisions	16,599	14,137	17,049	14,878
General expenses	11,346	10,281	12,822	13,656
	<b>293,231</b>	<b>224,167</b>	<b>318,516</b>	<b>284,973</b>

### 25. Financial instruments

The Company is generally exposed to the following operating risks that may affect its strategic and financial objectives to a greater or lesser extent:

- Market risk;
- Liquidity risk;
- Credit risk; and
- Operating risk.

The Company manages the risks to which it is exposed by defining conservative strategies to ensure liquidity, profitability, and safety, using objective criteria for risk diversification.

This note reports the Company's exposure to each of the above risks, and its objectives, policies and processes for risk measurement and management and for capital management.

#### Risk management structure

In line with current regulations and with the Company's corporate policies, the system is based on the integrated management of each of the business processes and on adjusting risk level to strategic objectives established. The Company's corporate governance structure involves an extensive risk management process for identifying, treating, and monitoring these risks that extends from senior management, and institutional committees such as the auditing committee, which is responsible, among other duties, for overseeing the integrity and effectiveness of internal control processes and risk management through to all the Company's different areas.

The Company's internal control environment has been designed to support the nature, risk, and complexity of its operations. It is based on formalized policies and procedures that are disseminated throughout the organization, as well as dedicated business areas and specific tools for risk monitoring.

Management of all risks inherent in the Company's activities on an integrated basis is addressed within a process supported by the structures of Internal Controls and Compliance (in relation to internal policies, rules, and regulations) that ensures continuous improvement for risk management models and minimizes any omission that could jeopardize correct risk identification and assessment. Based on identification, assessment and monitoring of the principal risks, the Company draws up specific action plans to ensure that improvements are implemented.

## Notes to quarterly information

To build the right control environment for the scale of its business, the Company invests to strengthen internal communication and disseminate the risk management concept among employees. Corporate risk management is supported by statistical tools with liability adequacy testing, stress testing, capital sufficiency indicators and others. In addition to these tools, the Company adds the qualitative side of risk management, with results from self-assessment, quality evaluations, and tests conducted by internal auditing to evaluate the effectiveness and efficiency of internal controls, as well as quality performance in fulfilling duties and responsibilities.

Historically, the financial instruments used by the Company have shown adequate results for risk mitigation. Additionally, the Company does not carry out transactions involving exotic or speculative derivatives.

- Market risks

These are risks related to assets and liabilities with cash flows or present values that are exposed to:

- a) Currency risk: Risk of loss or gain due to fluctuations in foreign currencies quotation. The main tool to control currency-related risk is the daily treasury position, which is based on reports provided by the BM&FBovespa and other sources (e.g. the Central Bank) for the control of exchange-rate fluctuations involved in the Company's transactions.
- b) Market risk - interest: Risk of fluctuating interest rates leading to increased expenses or decreased financial income. Fixed interest rates held to maturity reassure reliability of cash flows. Floating interest rates pose volatility for future interest charges. The main tool for control of risk related to interest rates is the daily treasury position, which is based on reports provided by the BM&FBovespa to control interest rates involved in the Company's transactions

The Company's main market risks arise from possible fluctuations in interest rates and exchange rates. As a result, the Company and its subsidiaries seek hedging for liquidity risk through financial instruments such as marketable securities, funding in the form of working capital loans, and funding through the issue of debentures, all on an arms' length basis.

The Company's market risk management practices are based on the operating strategies and internal controls established in its Internal Policy for Risk Management of Financial Assets ("Policy") in order to ensure liquidity, profitability, and safety of financial instruments exposed to risk. These practices consist of periodically monitoring of the Company's contractual conditions in comparison with current market conditions.

Every financial transaction is submitted to the Company's Executive Committee and subsequent validation by the Board of Directors and/or their auxiliary advisory committees. In the cases of exchange rate and interest-rate exposure, guidelines are set by the Board of Directors and operated by the Treasury Department, since they depend on variable components of the economic scenario. The Treasury Department forwards a monthly report to the Executive Committee showing the Company's current exposure to market risks and using reports, documents and contracts checks for compliance with the policy.

## Notes to quarterly information

In addition to the above, for market risks to which the Company is exposed, Treasury Department is mandated to run monthly stress tests assuming 25% and 50% variations in relation to original parameters in order to assess the elasticity of these positions when subjected to major variations of the rates involved in these transactions, and their impact on income and cash positions of the Company.

- Liquidity risk

Liquidity risk is the risk of an unforeseeable event or an error in calculating liquidity requirements that will impact the Company's investment decisions or day-to-day business.

The Company manages liquidity risk by maintaining adequate reserves, bank credit facilities, and credit lines from funding as deemed appropriate, continuously monitoring expected and actual cash flows and the combination of maturity profiles of financial assets and liabilities, following these guidelines:

- Short-term cash management - net assets and credit facilities to cover immediate needs. Periodicity: Daily. Term: D+1 (working days);
- Long-term cash management - Continuous process to ensure long-term funds, through analysis of the cash budget on a monthly basis, updating assumptions made in the budget in accordance with business needs, and comparing actual versus estimated performance. Periodicity: Monthly. Term: 5<sup>th</sup> working day of the month following the reporting date;
- Maintenance of minimum cash - Refers to cash balances the Company may replenish in a very short period of time to meet any urgent requirements. In addition, it uses the criterion that cash holdings must be sufficient to cover the five worst daily cash flows in a month, not including receivables;
- Exposure limits and risk mitigation - the treasury department keeps short-term facilities for immediate liquidity and working capital lines, so that volume is sufficient to ensure at least the amount equal to that of the highest cash outflow over five consecutive days in the past 12 months.

For medium and long term credit lines, the Treasury area maintains credit lines compatible with the Company's strategic planning, for the purpose of ensuring the availability of resources to meet the estimated cash flow.

The table below details the aging list of the consolidated financial liabilities at June 30, 2015:

### Consolidated

Operation	Maturity				Total
	2015	2016	2017 to 2018	From 2019 onwards	
Trade accounts payable	90,204	-	-	-	90,204
Bank loans and financing	150,238	9,472	28,403	7,704	195,817
Debentures	329,989	61,755	697,848	149,809	1,239,401
Taxes paid in installments	698	723	453	2,157	4,031
Payables for acquisition of subsidiary	1,071	18,556	4,370	116	24,113
	<b>572,200</b>	90,506	731,074	159,786	1,553,566

## Notes to quarterly information

- Credit risk

Refers to the risk of loss resulting from inability of the counterparty to meet its contractual obligations and make payments to the Company. The principal means of mitigating this risk is through the credit analysis process. Measurement of credit risk over time will be based mainly on the determination of the allowance for doubtful accounts.

The Company and its subsidiaries are subordinated to the credit policy set by its management and their purpose is to minimize any problems deriving from non-payment deriving from default due to disallowances of plans. The Company also set up an allowance for doubtful accounts due to disallowances, default and returned checks in the Company amounting to R\$61,808 (R\$44,366 at December 31, 2014) representing 9.22% (7.22% at December 31, 2014) from the balance of outstanding receivables in order to cover credit risk, and in consolidated R\$85,229 (R\$60,819 at December 31, 2014) representing 11.29% (8.80% at December 31, 2014) from the balance outstanding receivables in order to cover the credit risk.

At June 30, 2015, the maximum exposure in the consolidated was R\$1,117,800 (R\$966,197 at December 31, 2014) referring to cash and cash equivalents and receivables.

- Operational risk

Operational risk is the risk of direct or indirect losses arising from a variety of causes associated with our processes, personnel, technology and infrastructure, as well as external factors, other than credit, market and liquidity risks. It includes risks such as those arising from legal and regulatory requirements and generally accepted standards of corporate conduct. Operational risks arise from all of the Company's operations.

The objective of the Company is to manage operational risk to prevent the occurrence of financial losses or damage to its reputation while ensuring cost effectiveness and avoiding control procedures that hamper initiative and creativity.

The primary responsibility for developing and implementing controls to cover operational risk is attributed to senior management. The latter is supported by development of overall standards for operational risk management in the following areas:

- Requirements for appropriate segregation of duties, including independent authorization of transactions;
- Requirements for reconciliation and monitoring of transactions;
- Compliance with legal and regulatory requirements;
- Documentation of controls and procedures;
- Requirements for periodic assessment of operational risks faced, and adequacy of controls and procedures to treat the identified risks;
- Requirements for reporting transaction losses and proposed corrective measures;
- Developing contingency plans;
- Professional training and development;
- Ethical and business standards;
- Risk mitigation, including insurance, when effective.

## Notes to quarterly information

Compliance with the Company's rules is supported by a continuous quality assessment process and a program for periodical analysis of the Internal Auditing responsibilities. The results of the Internal Auditing analyses are discussed with the management of the related business unit, and reports are sent to the Auditing Committee and to the Company management.

### *Capital management*

The Company monitors the financial leverage to maintain a capital structure adequate to the operation and to reduce the indebtedness cost. The leverage ratio used corresponds to net debt divided by total equity.

The consolidated financial leverage at June 30, 2015 and December 31, 2014 are broken down as follows:

	<u>06/30/15</u>	<u>12/31/14</u>
Loans and financing (a)	195,817	166,000
Debentures (a)	<u>1,239,401</u>	<u>1,062,257</u>
Total gross debt	<u>1,435,218</u>	<u>1,228,257</u>
Cash and cash equivalents and marketable securities	<u>(623,899)</u>	<u>(440,225)</u>
Net debt	<u>811,319</u>	<u>788,032</u>
Equity	2,781,725	2,772,166
Contents	0.29166	0.28427

(a) Amounts are reported net of transaction costs.

The Company may alter its capital structure depending on economic-financial, strategic or operational conditions, in order to improve debt management. At the same time, the Company seeks to improve its Return on Capital Employed (ROCE) by implementing a working capital management and an efficient investment program.

The Company is subject to maximum indebtedness levels according to the terms presented in Note 18.

## Notes to quarterly information

### Financial instruments by category

The table below shows the Company's financial instruments by category. Fair values of financial instruments shown do not vary significantly from the balances shown in the Company and Consolidated balance sheets.

Description	Company					
	06/30/15			12/31/14		
	Fair value through profit or loss	Loans and receivables	Amortized cost	Fair value through profit or loss	Loans and receivables	Amortized cost
Cash and cash equivalents and marketable securities	471,028	-	-	307,368	-	-
Judicial deposits	64,534	-	-	61,267	-	-
Trade accounts receivable	-	608,907	-	-	570,501	-
<b>Assets</b>	<b>535,562</b>	<b>608,907</b>	<b>-</b>	<b>368,635</b>	<b>570,501</b>	<b>-</b>
Trade accounts payable	-	-	82,863	-	-	108,714
Bank loans and financing	-	-	101,664	-	-	85,923
Debentures	-	-	1,239,401	-	-	1,062,257
Taxes paid in installments	-	-	1,062	-	-	1,367
Accounts payable for acquisition of subsidiaries	-	-	13,474	-	-	23,920
<b>Liabilities</b>	<b>-</b>	<b>-</b>	<b>1,438,464</b>	<b>-</b>	<b>-</b>	<b>1,282,181</b>
Description	Consolidated					
	06/30/15			12/31/14		
	Fair value through profit or loss	Loans and receivables	Amortized cost	Fair value through profit or loss	Loans and receivables	Amortized cost
Cash and cash equivalents and marketable securities	642,494	-	-	465,780	-	-
Judicial deposits	66,268	-	-	62,934	-	-
Trade accounts receivable	-	669,764	-	-	629,506	-
<b>Assets</b>	<b>708,762</b>	<b>669,764</b>	<b>-</b>	<b>528,714</b>	<b>629,506</b>	<b>-</b>
Trade accounts payable	-	-	90,204	-	-	116,275
Bank loans and financing	-	-	195,817	-	-	166,000
Debentures	-	-	1,239,401	-	-	1,062,257
Taxes paid in installments	-	-	4,031	-	-	4,515
Accounts payable for acquisition of subsidiaries	-	-	24,113	-	-	34,048
<b>Liabilities</b>	<b>-</b>	<b>-</b>	<b>1,553,566</b>	<b>-</b>	<b>-</b>	<b>1,383,095</b>

### Fair value hierarchy

The Company holds only financial instruments qualified at level 2, corresponding to marketable securities in the consolidated amounts of R\$578,081 at June 30, 2015 (R\$445,721 at December 31, 2014).

The following different levels were defined:

- Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.



## Notes to quarterly information

- Level 2 - Inputs, other than quoted prices included in Level 1, that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions, for the asset or liability, which is not based on observable market, inputs (unobservable inputs).

There was no change in classification of levels during the first half of 2015.

### *Estimated market values*

Estimated market value for financial instruments was developed using a pricing model applied individually to each transaction, taking into account future payment flows based on contractual terms, discounted to present value at rates obtained through the market interest curve, based on information obtained from the BM&FBovespa and ANBIMA websites.

Therefore a security's market value corresponds to its value at maturity (redemption value) brought to present value using a discount factor (related to the maturity date) obtained from the market interest curve in Reais.

### Sensitivity analysis of financial assets and liabilities

Major risks concerning the Company's operations relate to Interbank Deposit Certificate (CDI) rate variations for promissory notes, debentures and marketable securities pegged to the dollar exchange rate fluctuation for bank loans and financing and marketable securities.

CDI investments are recognized at market value, as per quotations disclosed by the related financial institutions, whereas others refer mostly to Bank Deposit Certificates (CDB) and repurchase agreements and, as such, their recorded amount does not differ from market value.

Based on expectations stated in the FOCUS/Bacen report of 06/26/2015, a projection for the next 12 months was obtained, with an average of 13.21% for CDI and R\$3.30 for the exchange rate (R\$/US\$).

In order to verify the sensitivity of the index on marketable securities held by the Company at June 30, 2015, three different scenarios were defined, based on the projection and, from then on, the variations of 25% and 50% were calculated.

Gross financial expense/(financial income) was calculated for each scenario not including the impact of taxes and the maturity flow of each contract scheduled for 2015.

<b>Transaction</b>	<b>Balance at 06/30/15</b>	<b>Risk (a)</b>	<b>Scenario I (Probable)</b>	<b>Scenario II</b>	<b>Scenario III</b>
Marketable securities	56,869	USD	(3,618)	14,217	28,434
			3.30	2.33	1.55
Marketable securities	502,617	CDI	66,396	49,797	33,198
			13.21%	9.91%	6.61%

In order to verify the sensitivity of our debts index at June 30, 2015, three scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

**Notes to quarterly information**

Gross financial expense was calculated for each scenario, not taking into consideration the impact of taxes and the flow of maturities of each contract scheduled for 2015. The reporting date used for financing was June 30, 2015, and the indices were projected for one year and their sensitivity determined for each scenario.

Transaction	Balance at 06/30/15	Risk (a)	Scenario I (Probable)	Scenario II	Scenario III
Debentures	1,244,394	CDI	164,384	205,481	246,577
			13.21%	16.51%	19.82%
Financing of working capital	87,930	CDI	11,615	14,519	17,423
			13.21%	16.51%	19.82%
Financing of working capital	94,153	USD	5,990	23,538	47,077
			3.30	3.88	4.65

(a) Rate subject to variation

Fair value

	Company			
	06/30/15		12/31/14	
	Book value	Fair value	Book value	Fair value
<b>ASSETS</b>				
Marketable securities	453,083	453,083	290,245	290,245
Judicial deposits	64,534	64,534	61,267	61,267
Trade accounts receivable	608,907	608,907	570,501	570,501
<b>LIABILITIES</b>				
Trade accounts payable	82,863	82,863	108,714	108,714
Debentures	1,239,401	1,236,951	1,062,257	1,054,967
Loans and financing:				
Other bank loans	101,664	146,397	85,923	85,934
<b>Consolidated</b>				
	06/30/15		12/31/14	
	Book value	Fair value	Book value	Fair value
	Book value	Fair value	Book value	Fair value
<b>ASSETS</b>				
Marketable securities	578,081	578,081	445,721	445,721
Judicial deposits	66,268	66,268	62,934	62,934
Trade accounts receivable	669,764	669,764	629,506	629,506
<b>LIABILITIES</b>				
Trade accounts payable	90,204	90,204	116,275	116,275
Debentures	1,239,401	1,236,951	1,062,257	1,054,967
Loans and financing:				
Bank loan - Banco do Brasil	36,077	35,185	71,650	71,661
Bank loan - Banco Santander	51,853	51,704	-	-
Bank loan - Credit Agricole	94,153	94,153	80,078	80,078
Other bank loans	13,734	13,734	14,272	14,272
	195,817	194,776	166,000	166,011

## Notes to quarterly information

### 26. Related parties

During the periods ended June 30, 2015 and 2014 the Company entered into transactions with related parties within its ordinary operating context, as shown below:

a) Transactions related to services rendered between Company and related parties

	<u>06/30/15</u>	<u>12/31/14</u>
<b>Current assets - customers</b>		
CientificaLab	843	684
CERPE	223	197
Previlab	107	77
Lafê	-	2,843
	<u>1,173</u>	<u>3,801</u>
<b>Current liabilities – Other accounts payable</b>		
DASA RE (i)	84	82
	<u>84</u>	<u>82</u>
<b>Income for the period</b>	<b>06/30/15</b>	<b>06/30/14</b>
<b>Service revenue</b>		
CientificaLab	4,131	312
CERPE	615	536
Previlab	561	374
	<u>5,307</u>	<u>1,222</u>
<b>Costs of services rendered</b>		
DASA RE (i)	492	448
CRMI Petrópolis (ii)	223	-
Sérgio Franco (ii)	-	18,304 (iii)
	<u>715</u>	<u>18,752</u>

(i) Amounts corresponding to property rent.

(ii) Amounts corresponding to clinical analysis services.

(iii) Amounts corresponding to clinical analysis services until 06/30/2014.

**Transactions with related parties, as shown above, are carried out at cost and eliminated in the consolidated financial statements.**

b) Future capital contributions (FCC)

	<u>06/30/15</u>	<u>12/31/14</u>
Check-UP Unidade Preventiva Ltda	500	61,000

c) Loan agreements between the Company and its subsidiaries at June 30, 2015

<u>Borrower</u>	<u>Balance</u>	<u>Maturity</u>	<u>Rate</u>
CERPE	4,158	2019	100% of CDI

## Notes to quarterly information

### d) Management compensation

Management compensation, including fixed compensation and bonuses, totaled R\$1,812 for the first half of 2015 (R\$1,332 for the first half of 2014) paid to the members of the Board of Directors (6 members in the first half of 2015 and 5 members in the first half of 2014), and R\$6,351 for the first half of 2015 and R\$5,800 for the first half of 2014 paid to statutory officers (11 officers in the first half of 2015 and of 2014).

Changes in share-based payments are disclosed in Note 21(a). There are no additional benefits to the Company's management members.

### e) Transactions between the Company and other related parties

Related-party transactions are conducted at amounts, terms and rates agreed upon between the parties, and effective on the respective dates, under continuing conditions.

The related parties included in the consolidated financial statements are:

- Soldiers Field Serviços Administrativos Ltda.: entity held by Marcelo Noll Barboza, a member of the Company's Board of Directors and Statutory Audit Committee since July 24, 2014. Payments arise from the obligations set forth in an arrangement entered into with Company by virtue of the tenure expiration, on April 27, 2012, of the Chief Executive Officer (took office on October 1, 2008), Chief Financial Officer and Investor Relations Officer (both since February 13, 2012). On June 22, 2015, the Company paid R\$328 related to the last installment of such commitment.
- Link Consultoria em Medicina Diagnóstica Ltda.: entity held by Alcione Moya Aprilante, member of Previlab Análises Clínicas Ltda., which is a subsidiary of the Company. It provides advisory services regionally in the management of health companies, and has market know-how, relationship with physicians practicing in the region where Previlab operates, as well as recognition by potential health professionals and customers.
- Medparts Participações e Negócios Ltda.: entity held by Doctor Luciano Flávio Freitas de Almeida, member of Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. - CERPE, which renders services to the Company, providing advisory services on business management of medical companies, with market know-how, relationship with local physicians, and recognition of potential professionals and customers in the healthcare field.
- Amar Administradora de Bens Próprios Ltda.: entity held by Doctor Alcione Moya Aprilante and his wife, Melania Angeliari Cunha Aprilante. Doctor Alcione is a member of Previlab (a subsidiary of Company) which is lessor of the properties owned by AMAR, which were owned by Melania Angeliari Cunha Aprilante.
- César Antonio Biazio Sanches: member of Previlab Análises Clínicas Ltda., owner of the property leased by Previlab, a subsidiary of Company.
- A e C Consultores Ltda.: an entity held by Cezar Antonio Biázio Sanches, member of Previlab Análises Clínicas Ltda., which is a subsidiary of Company. It provides business advisory and support services in the Previlab business area, as well as advisory, coaching, training and assessment of Previlab's employees and service providers.

## Notes to quarterly information

- **Pesmed - Pesquisas e Serviços Médicos Ltda.:** a Company controlled by Mr. Emerson Leandro Gasparetto, our radiology and graphical methods officer (elected on March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, for consulting services in the form of medical research and surveys for former subsidiaries (merged on July 1, 2014): CDPI - Clínica de Diagnósticos por Imagem Ltda., CRMI - Clínica de Ressonância e Multi Imagem Ltda. The amounts are calculated based on the number of reports actually prepared by Pesmed, with due regard for the amount corresponding to each type of report, as per the list prepared by Company, using the same system adopted for the other providers of services for the Company.
- **RMR Ressonância Magnética Ltda.:** a Company with shareholders jointly holding 80% of its capital who are the brothers of Mr. Romeu Cortês Domingues, chairman of the Board of Directors of the Company (elected on April 26, 2011), which provides medical services in the field of magnetic resonance imaging for these former subsidiaries (merged on July 1, 2014): CDPI - Clínica de Diagnósticos por Imagem Ltda.; CRMI - Clínica de Ressonância e Multi Imagem Ltda.; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Amounts are calculated based on revenue from magnetic resonance imaging services and numbers of exams produced by RMR, recognizing the corresponding charge for each type of report, as per the list prepared by the Company and using the same system adopted for the other providers of services for the Company.
- **Ultrascan Serviços de imagem Ltda.:** Company owned by Eduardo Luiz Primo de Siqueira, who holds 7.5% of Clínica de Ressonância Multi-Imagem Petrópolis Ltda, which provides medical services in the imaging area for the controlled Company Clínica de Ressonância Multi-Imagem Petropolis Ltda. The amounts are calculated based on the imaging service revenue and the number of reports prepared by Ultrascan, subject to the amount corresponding to each report type, according to the subsidiary's table, and they should further comply with the same system adopted for the other service providers of subsidiary.
- **DMG Laboratório Médico Ltda.:** a franchise of Laboratórios Médicos Dr. Sérgio Franco Ltda. brand, whose managing partner is Neusa de Godoy Bueno Joaquim, mother-in-law of the regional chief financial officer of such brand that was merged on July 1, 2014. The franchise commission is calculated based on DMG's service revenue, subject to the same system adopted for the other franchisees.
- **Lâmina Laboratório de Patologia Prevenção de Câncer Ltda.:** an entity whose partner is Adilia Jane de Alcantara Segura, non-statutory medical officer of the Company, for clinical pathology services. The amounts are calculated based on the number of examinations effectively made by Lâmina, subject to the amount corresponding to each examination type, according to the Company table and pursuant to the same system adopted for the other services providers. Since 2013 no transactions have been carried with the Company; the agreement, however, remains effective.
- **ECRD - Serviços Médicos de Radiologia Ltda.:** The Company's partner is Mr. Roberto Cortes Domingues, brother of Mr. Romeu Cortês Domingues, chairman of the Board of Directors, which provides medical services referring to MRI and radiology for former subsidiaries (merged on July 1, 2014) CDPI - Clínica de Diagnósticos por Imagem Ltda., CRMI - Clínica de Ressonância e Multi Imagem Ltda.; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Clínica de Ressonância and subsidiary Multi-Imagem Petropolis Ltda.

## Notes to quarterly information

- Grupo Amil (Amil Internacional; Amil Par; Amico and Dix): Mr. Edson Godoy Bueno, together with Dulce Pugliese de Godoy Bueno, is the controlling shareholder of the Company and the Chief Executive Officer of Amil Group, for which the Company and its subsidiaries provide diagnostic medicine services. The Company and its subsidiaries also engage healthcare plan management services from Amil Group for their employees.
- Amil Impar: Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, the Company's shareholders and also the controlling members of Amil Impar, which holds interest in hospitals where the Company and its subsidiaries provide diagnostic medicine services.
- Patrys Investimentos Imobiliários Ltda. (formerly EGB 01 Empreendimentos e Participações Ltda.): Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, controlling shareholders of Company and of EGB, which owns properties leased under a free lease agreement with Company and its subsidiaries.

Following are the amounts corresponding to transactions with the companies above:

	Assets/ (Liabilities)			Assets/ (Liabilities)		
	06/30/2015			12/31/2014		
	Services	Rents	Healthcare	Services	Rents	Healthcare
Soldiers Field Serviços Administrativos Ltda.	-	-	-	160	-	-
Soldiers Field Serviços Administrativos Ltda.	-	-	-	(389)	-	-
Link Consult. em Medicina Diag. Ltda.	-	-	-	(15)	-	-
Medparts Particip. e Negócios Ltda.	-	-	-	(22)	-	-
Amar Admin. de Bens Próprios Ltda.	-	(30)	-	-	(28)	-
César Antonio Biazio Sanches	-	(6)	-	-	(6)	-
A e C Consultores Ltda.	(5)	-	-	(35)	-	-
DMG Laboratório Médico Ltda.	-	-	-	27	-	-
Grupo AMIL (AMIL Internacional; Amil Par, Amico e Dix)	(a) <b>104,815</b>	-	<b>(1,745)</b>	80,308	-	(114)
AMIL Impar	(a) <b>20,607</b>	-	-	6,114	-	-
Patrys Investimentos Imobiliários Ltda.	-	<b>(450)</b>	-	-	(449)	-

(a) The amount under assets balances for services rendered by the Company and its subsidiaries is net of the provision for disallowance, as well as financial discounts.

	Income / (Expenses)			Income / (Expenses)		
	06/30/15			06/30/14		
	Services	Rents	Healthcare	Services	Rents	Healthcare
Soldiers Field Serviços Administrativos Ltda.	(100)	-	-	(183)	-	-
Link Consult. em Medicina Diag. Ltda.	(95)	-	-	(79)	-	-
Medparts Particip. e Negócios Ltda.	(136)	-	-	(133)	-	-
Amar Admin. de Bens Próprios Ltda.	-	(169)	-	-	(152)	-
César Antonio Biazio Sanches	-	(46)	-	-	(55)	-
A e C Consultores Ltda.	(220)	-	-	(208)	-	-
Pesmed - Pesquisas e Serv. Médicos Ltda.	(137)	-	-	(142)	-	-
RMR Ressonância Magnética Ltda.	(1,091)	-	-	(848)	-	-
Ultrascan Serviços de imagem Ltda.	(107)	-	-	(95)	-	-
DMG Laboratório Médico Ltda.	(283)	-	-	(257)	-	-
ECRD – Serviços Médicos de Radiologia Ltda.	(1,227)	-	-	(900)	-	-
Grupo AMIL (AMIL Internacional; Amil par, Amico e Dix)	<b>271,657</b>	-	<b>(22,242)</b>	250,325	-	(16,278)
AMIL Impar	<b>19,966</b>	-	-	17,398	-	-
Patrys Investimentos Imobiliários Ltda.	-	<b>(3,228)</b>	-	-	(2,993)	-

## Notes to quarterly information

### 27. Finance and operating lease agreements

#### Local finance lease

The Company leases goods recorded in property and equipment, with purchase option, no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. These contracts total a balance payable of R\$1,506 until 2016 in the Company and consolidated, given that R\$1,187 of this amount is recorded in current liabilities and R\$319 in noncurrent liabilities.

The average term of the contracts is 36 months and they bear interest rates of CDI + 2.03% p.a.

Future minimum payments under loans and financing (see Note 17) are segregated as follows:

	06/30/15					
	Company			Consolidated		
	Present value of minimum payments	Interest	Future minimum payments	Present value of minimum payments	Interest	Future minimum payments
Within 1 year	1,187	189	1,376	1,187	189	1,376
From 1 to 5 years	319	51	370	319	51	370
	<b>1,506</b>	<b>240</b>	<b>1,746</b>	<b>1,506</b>	<b>240</b>	<b>1,746</b>
	12/31/14					
	Company			Consolidated		
	Present value of minimum payments	Interest	Future minimum payments	Present value of minimum payments	Interest	Future minimum Future
Within 1 year	3,048	427	3,475	3,048	427	3,475
From 1 to 5 years	749	105	854	749	105	854
	<b>3,797</b>	<b>532</b>	<b>4,329</b>	<b>3,797</b>	<b>532</b>	<b>4,329</b>

The local finance lease agreements are included in property and equipment as machinery and equipment, totaling R\$2,428 (R\$9,468 at December 31, 2014) in consolidated.

#### Foreign finance lease

The Company leases equipment used to provide services, according to lease agreements with purchase option, no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. The payment term is 84 months and for the first installment of a shortage of 6 months for the settlement was established, and the remaining payments on a quarterly and semiannual basis. The quarterly and semiannual installments in US dollars are translated into reais at the market exchange rate effective on the payment date, plus interest of 2.97% p.a., the balance payable totaling R\$444 by 2016, recorded under current liabilities.

**Notes to quarterly information**

Future minimum payments are segregated as follows:

	06/30/15					
	Company			Consolidated		
	Present value of minimum payments	Interest	Future minimum payments	Present value of minimum payments	Interest	Future minimum payments
Within 1 year	444	13	457	444	13	457
	12/31/14					
	Company			Consolidated		
	Present value of minimum payments	Interest	Future minimum payments	Present value of minimum payments	Interest	Future minimum payments
	Within 1 year	1,978	89	2,067	1,978	89
From 1 to 5 years	84	4	88	84	4	88
	2,062	93	2,155	2,062	93	2,155

The foreign finance lease agreements are included in property and equipment as machinery and equipment, totaling R\$153 (R\$3,776 at December 31, 2014) in consolidated.

Operating lease

Future minimum property rent payable on operating leases not subject to cancellation in consolidated are the following:

	06/30/15			12/31/14		
	Fixed-income agreements	Variable-income agreements	Total	Fixed-income agreements	Variable-income agreements	Total
Within 1 year	133,728	1,613	135,341	137,795	2,499	140,294
From 1 to less than 5 years	270,489	3,261	273,750	336,264	6,099	342,363
More than 5 years	152,466	-	152,466	120,361	1,791	122,152
	556,683	4,874	561,557	594,420	10,389	604,809

**28. Operating revenue**

Below is the reconciliation between gross revenues for tax purposes and net revenues, and selling discounts presented in the income statement for the period:

	Company		Consolidated	
	06/30/15	06/30/14	06/30/15	06/30/14
Gross revenue	1,453,594	1,054,912	1,565,508	1,476,878
Deductions:				
Taxes	(86,029)	(61,593)	(93,234)	(85,287)
Provision for disallowance and default	(18,811)	7,603	(24,495)	(610)
Losses due to disallowance and default	(37,968)	(36,088)	(46,092)	(36,715)
Discounts	(19,085)	(3,203)	(19,158)	(4,720)
	1,291,701	961,631	1,382,529	1,349,546



**Notes to quarterly information****29. Financial income (expenses)**

	<b>Company</b>		<b>Consolidated</b>	
	<b>06/30/15</b>	<b>06/30/14</b>	<b>06/30/15</b>	<b>06/30/14</b>
<b>Financial expenses</b>				
Interest	<b>(94,844)</b>	(72,423)	<b>(97,447)</b>	(75,481)
Monetary and exchange losses	<b>(1,086)</b>	(864)	<b>(194)</b>	(1,369)
Discounts granted (a)	-	(2,304)	-	(6,025)
Other	<b>(5,614)</b>	(5,242)	<b>(4,976)</b>	(9,434)
	<b>(101,544)</b>	(80,833)	<b>(102,617)</b>	(92,309)
<b>Financial income</b>				
Interest	<b>42,337</b>	27,532	<b>52,529</b>	36,415
Monetary and exchange gains	<b>997</b>	1,069	<b>997</b>	1,429
Other	<b>587</b>	427	<b>582</b>	1,411
	<b>43,921</b>	29,028	<b>54,108</b>	39,255
	<b>(57,623)</b>	(51,805)	<b>(48,509)</b>	(53,054)

Discounts granted to customers in the first half of 2014, amounting to R\$2,276 in the Company and R\$5,980 in the consolidated, due to business negotiation.

Pedro de Godoy Bueno  
Chief Executive Officer

Carlos de Barros Jorge Neto  
Chief Administrative, Financial and Investor  
Relations Officer

Carlos Elder Maciel de Aquino  
Accounting Management and Accounts Receivable Officer

**Daniel Vendramini da Silva**  
**TC-CRC 1SP125812/O-1**

**Other Information Considered Relevant by the Company****Shareholding structure**Controlling shareholders, managing officers and outstanding shares

Shareholders	Position at June 30, 2015			
	Common shares (unit)	%	Total shares (unit)	%
Controllers	224,308,396	71.94%	224,308,396	71.94%
Board of directors	7,494,234	2.40%	7,472,934	2.40%
Staff of officers	105,204	0.03%	105,204	0.03%
Statutory Audit Committee	1	0.00%	1	0.00%
Treasury stock	1,052,459	0.34%	1,052,459	0.34%
Outstanding shares	78,842,721	25.29%	78,842,721	25.29%
<b>Total of shares</b>	<b>311,803,015</b>	<b>100.00%</b>	<b>311,803,015</b>	<b>100.00%</b>

  

Shareholders	Position at June 30, 2014			
	Common shares (unit)	%	Total shares (unit)	%
Controllers	224,308,396	71.94%	224,308,396	71.94%
Board of directors	7,449,953	2.39%	7,449,953	2.39%
Staff of officers	111,728	0.03%	111,728	0.03%
Statutory Audit Committee	1	0.00%	1	0.00%
Treasury stock	1,052,459	0.34%	1,052,459	0.34%
Outstanding shares	78,880,478	25.30%	78,880,478	25.30%
<b>Total of shares</b>	<b>311,803,015</b>	<b>100.00%</b>	<b>311,803,015</b>	<b>100.00%</b>

At June 30, 2015 and 2014, the Company did not have a Supervisory Board.

Arbitration clause

The Company is bound to arbitration by the Market Arbitration Chamber, pursuant to the arbitration clause provided for in its articles of incorporation.

## **Independent auditor's review report on quarterly financial information**

**A free translation from Portuguese into English of Independent Auditor's Report on Financial Statements prepared in Brazilian currency in accordance with accounting practices adopted in Brazil.**

---

## **Independent auditor's review report on quarterly financial information**

The Shareholders, Board of Directors and Officers

**Diagnósticos da América S.A.**

São Paulo - SP

### **Introduction**

We have reviewed the accompanying individual and consolidated interim financial information of Diagnósticos da América S.A. ("Company") and subsidiaries, contained in the Quarterly Information Form (ITR) for the quarter ended June 30, 2015, which comprises the balance sheet as at June 30, 2015 and the related statements of income and of comprehensive income for the three and six-month periods then ended, the statements of changes in equity and cash flows for the six-month period then ended, including explanatory information.

Management is responsible for the preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the presentation of this financial information in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

### **Scope of review**

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## **Independent auditor's review report on quarterly financial information**

### **Conclusion on the individual and consolidated interim financial information**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of Quarterly Information (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).

### **Other matters**

#### **Statements of value added**

We have also reviewed the individual and consolidated statement of value added (SVA) for the six-month period ended June 30, 2015, prepared under the responsibility of Company management, the presentation of which in the interim financial information is required by the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to preparation of Quarterly Information (ITR) and as supplemental information under the IFRS, whereby no SVA presentation is required. These statements have been subject to the same review procedures previously described and, based on our review, nothing has come to our attention that causes us to believe that they are not prepared, in all material respects, consistently with the accompanying overall individual and consolidated interim financial information.

São Paulo, August 10, 2015.

ERNST & YOUNG  
Auditores Independentes S.S.  
CRC-2SP015199/O-6

Antonio Carlos Fioravante  
Accountant CRC-1SP184973/O-0

Rita de C. S. de Freitas  
Accountant CRC-1SP214160/O-5

**Opinions and statements/Statement of officers on the quarterly information**

Observing the provision of article 25 of Ruling No. 480/09 of December 7, 2009, the Board represents that it has reviewed, discussed and agreed with the Quarterly information (Company and Consolidated) for period ended June 30, 2015.

Barueri, August 10, 2015.

Chief Executive Officer - Pedro de Godoy Bueno

Chief Administrative, Financial and Investor Relations Officer - Carlos de Barros Jorge Neto

Accounting Management and Accounts Receivable Officer - Carlos Elder Maciel de Aquino

**Opinions and declarations/Statement of officers on the independent auditors report**

In compliance with the provisions of article 25, Instruction # 480/09, of December 7, 2009, the Staff of Officers represents that it has reviewed, discussed and agreed with the opinion expressed in the Independent Auditors' Review Report, dated August 10, 2015, related to the quarterly information (Company and Consolidated) for the period ended on June 30, 2015.

Barueri, August 10, 2015.

Chief Executive Officer – Pedro de Godoy Bueno

Chief Administrative, Financial and Investor Relations Officer – Carlos de Barros Jorge Neto

Accounting Management and Accounts Receivable Officer - Carlos Elder Maciel de Aquino